Chimeric immunogens and methods for producing polyclonal antibodies against specific epitopes - Patents.com

Abstract

In alternative embodiments, chimeric immunogens or antigens and methods of making and using them are provided, including methods of making and obtaining polyclonal antibodies specific for selected epitopes. In alternative embodiments, methods of generating an epitope-specific antibody response in rabbits are provided, the immune response comprising the generation of rabbit antibodies specific for (or specifically binding to) at least one human epitope, the methods comprising administering to the rabbit a chimeric or recombinant polypeptide in an amount sufficient to generate an epitope-specific antibody response. In alternative embodiments, chimeric or recombinant polypeptides are provided that include a ferritin polypeptide to which an immunogenic peptide or polypeptide is conjugated or attached by or through a substantially non-immunogenic linker.

Description

[Technical field]

[0001] Related Applications This PCT international utility patent application claims the benefit of priority under 35 U.S.C. §119(e) to U.S. Provisional Patent Application No. (USSN) 63 / 183,616, filed May 3, 2021. The aforementioned application is incorporated herein by reference in its entirety and for all purposes.

[0002] The present invention relates generally to immunology and immunoassays. In an alternative embodiment, chimeric immunogens and methods of making and using them are provided, including methods of making and obtaining polyclonal antibodies specific to selected epitopes. In an alternative embodiment, a method of generating an epitope-specific antibody response in rabbits is provided, the immune response comprising the generation of rabbit antibodies specific for (or specifically binding to) at least one human epitope, the method comprising administering to the rabbit a chimeric or recombinant polypeptide in an amount sufficient to generate an epitope-specific antibody response. In an alternative embodiment, a chimeric or recombinant polypeptide is provided comprising a ferritin polypeptide to which an immunogenic peptide or polypeptide is conjugated or linked by or through a substantially non-immunogenic linker. [Background technology]

[0003] Polyclonal antibodies have diverse reactivity to multiple epitopes, ensuring a robust response even when exposed to target diversity or environmental changes. To obtain polyclonal antibodies, animals are immunized with proteins, protein fragments, or mixtures thereof, after which the humoral immune system selects antibody-producing B-cell clones for expansion and maturation. These B cells are further diversified at a later stage by mutagenesis and selection of high-affinity immunoglobulin genes. Although the immune system has the basic ability to make antibodies against almost all foreign proteins, it is known that some epitopes are dominant, and that B-cell clones producing antibodies that recognize these "dominant" epitopes become dominant in the immune response. This means that standard polyclonal antibodies may be biased towards some epitopes and lack reactivity against others.

[0004] In principle, immunization can be achieved by using a single (e.g. linear) epitope using a single peptide or a mixture of peptides. However, peptides may not have the same three-dimensional (3D) structure as the protein from which they are derived, and therefore may cause the production of antibodies with reduced or no affinity to the protein. Peptides (especially those that are not dominant epitopes) are often too small to elicit an immune response by themselves and must be incorporated into larger structures or rely on co-stimulation with more immunogenic components to stimulate the immunized animal to produce antibodies against other than the dominant epitope prioritized by the humoral response.

[0005] Although it is possible to achieve tolerization to non-selected epitopes using various techniques, such as neonatal tolerization, drug-induced tolerization, masking subtractive immunization, or high zone tolerization methods (see, for example, U.S. Pat. Nos. 7,598,030 and 8,133,744), tolerization can be a leaky process in which antibody clones against non-selected epitopes continue to appear at some level, and it has been suggested to use combinations to obtain higher efficiency. In either case, tolerization means that an additional step is required as part of the process, in addition to standard immunization, increasing complexity and cost.

[0006] Antibodies for commercial use are purified from the serum of immunized animals. Even though total immunoglobulin can be extracted, it is often necessary to further purify the antibodies by reducing undesired reactivities (adsorption purification) or by specifically selecting for desired reactivities (affinity purification).

[0007] It would be advantageous to be able to designate the particular epitope that a polyclonal antibody recognizes without having to add additional steps to the immunization and / or purification process, e.g., to eliminate the need for costly and time-consuming adsorption and / or affinity purification steps. Summary of the Invention

[0008] In an alternative embodiment, a chimeric or recombinant polypeptide comprising: (a) a polypeptide derived from a first species, and (b) at least one heterologous amino acid sequence or amino acid residue derived from at least a second species; at least one heterologous amino acid sequence or amino acid residue from a second or additional species is inserted into, joined to, engineered into, or replaces or substitutes a portion of the amino acid sequence of the polypeptide from the first species; the amino acid sequence of the chimeric or recombinant polypeptide consists essentially of an amino acid sequence derived from a first species, the amino acid sequence from the second species when inserted into, joined to, created into, or replacing or substituting a portion of the amino acid sequence of the polypeptide from the first species generates, forms, or creates at least one new epitope on the polypeptide from the first species, which at least one new epitope is capable of generating a humoral antibody response by the first species specific for the at least one new epitope when the chimeric or recombinant polypeptide is administered to the first species; When the chimeric or recombinant polypeptide is used to generate a humoral immune response from an animal of a first species, the polyclonal antibodies so generated in the first species are provided which bind specifically substantially only to the at least one new epitope and do not specifically bind, or do not substantially specifically bind, or bind only with low affinity to a polypeptide from the first species that lacks the at least one new epitope or epitopes generated, formed, or generated by at least one heterologous amino acid sequence or amino acid residue from a second or additional species that is inserted into, joined to, engineered into, or replaces or substitutes a portion of the polypeptide from the first species. In other words, there may be some low affinity and / or non-specific binding of the newly generated antibodies in the first species to proteins against the polypeptide from the first species that does not contain therein a protein sequence that forms the at least one new epitope from the second species.

[0009] Another possible scenario may occur when using a protein domain such as the constant domain of a light chain (as a polypeptide from a first species) for immunization, in which case an antibody response may be generated against a surface that is not normally exposed in the first species (e.g., not normally exposed when the protein is normally folded or in its native three-dimensional (3D) structure in a physiological environment). For example, a surface that is not normally exposed in the constant region is the linker region (the region that connects the variable and constant domains) between the constant and variable domains of the lambda light chain and the C-terminal cysteine ​​that is normally linked to the heavy chain in intact IgG. That is, when a domain is removed from its normal environment, a humoral response may be generated against one or more surfaces that are exposed thereby (in a chimeric or recombinant polypeptide). Importantly, this may result in antibody production against newly exposed homologous sequences in the immunogen (e.g. rabbit homologous sequences such as the rabbit constant domain of the lambda light chain), but should not induce a humoral response that recognizes the normal (normally folded) light chain, since these regions (the normally non-exposed surface) are hidden or folded in their native 3D structure.

[0010] In an alternative embodiment of the chimeric or recombinant polypeptide provided herein, - the polypeptide from the second species is a homologue of the polypeptide from the first species, - at least one amino acid sequence from a second species is homologous to the first species and is inserted into, joined to, engineered into, or replaces or substitutes a portion of the amino acid sequence of the polypeptide from the first species, wherein the at least one homologous second species sequence replaces all or substantially all of the structurally homologous section or portion of the amino acid sequence of the polypeptide from the first species; - at least one amino acid sequence from a second species is homologous to the first species, and at least one homologous second species sequence that is inserted into, joined to, engineered into, or replaces or substitutes a portion of the amino acid sequence of a polypeptide from the first species is structurally homologous to the amino acid sequence of the polypeptide from the first species; - the homologue of the first species has at least about 25% to 99% sequence identity to its homologue in the second species; - the homologue in the first species has substantially the same secondary and / or tertiary structure as its homologue in the second species; - the homologue of the first species has at least about 25% to 99% sequence identity to its homologue in the second species and has substantially the same secondary and / or tertiary structure as its homologue in the second species; - the homologue in the first species has at least about 50% sequence identity to its homologue in the second species, or the homologue in the first species has at least about 70% sequence identity to its homologue in the second species, or the homologue in the first species has at least about 80% sequence identity to its homologue in the second species, or the homologue in the first species has at least about 90% sequence identity to its homologue in the second species; - the first polypeptide and the second polypeptide have a Z-score of about 2 to about 8 when aligned using a distance matrix alignment, or the first polypeptide and the second polypeptide have a Z-score of at least 8 when aligned using a distance matrix alignment; - the polypeptide from the first species and its homologous polypeptide from the second species are antibodies or the polypeptide from the first species and the at least one heterologous amino acid sequence from the second species are derived from an antibody heavy chain or an antibody light chain, - the antibody heavy chain is an IgM, IgG, IgA or IgE isotype heavy chain, or the light chain is a kappa or lambda light chain, - the first species is a mammalian species and the second species is a mammalian species, or the first species is a species of the order Galliformes or Phasianidae and the second species is a mammalian species, or the first species is a rabbit, a murine species, a sheep, a goat, a pig, a cow, a horse, or a chicken and the second species is a human, or the murine species is a rat or a mouse; - at least about 80% to about 99% of the amino acid sequence of the chimeric or recombinant polypeptide is an amino acid sequence derived from a first species, and / or between about 1% and about 20% of the amino acid sequence of the chimeric or recombinant polypeptide is an amino acid sequence derived from at least one second species; - one, two, three, four, five, six, seven, eight or more new epitopes are inserted into, joined to, engineered into, or replace or substitute for a portion of the polypeptide from the first species; - at least one new epitope comprises an epitope derived from a cryptic surface of an antibody light chain, the cryptic surface being only exposed when the antibody light chain is free and not part of an IgG molecule that contains both a light chain and a heavy chain; - the epitope is generated, created or formed by at least one heterologous amino acid sequence derived from at least one second species, (a) aligning the sequence of a polypeptide from a first species with its homologue polypeptide from a second species; (b) determining one or more amino acid sequence differences between a polypeptide from a first species and its homologue polypeptide from a second species; (c) selecting at least one amino acid sequence difference between a polypeptide from a first species and its homologue polypeptide from a second species; and (d) modifying the sequence of a polypeptide derived from a first species to match or be identical to at least one selected amino acid sequence from a homologous polypeptide of a second species. Designed by - selecting at least one amino acid sequence difference between the polypeptide derived from the first species and its homologue polypeptide derived from the second species comprises highlighting the determined one or more amino acid sequence differences between the polypeptide derived from the first species and its homologue polypeptide derived from the second species on a 3D model or structure of the polypeptide derived from the second species, and selecting at least one amino acid sequence difference in or on an exposed or outer surface of the polypeptide; - at least one amino acid sequence from a second species which is inserted into, joined to, engineered into, or replacing or substituting a portion of the amino acid sequence of the polypeptide from the first species comprises a sequence present in human IgG3 and absent in human IgG1, IgG2 or IgG4, or rabbit IgG, a sequence present in human IgG1 and absent in human IgG2, IgG3 or IgG4, or rabbit IgG, a sequence present in human IgG2 and absent in human IgG1, IgG3 or IgG4, or rabbit IgG, or a sequence present in human IgG4 and absent in human IgG1, IgG2 or IgG3, or rabbit IgG, - for example, as shown in Figure 8, a chimeric or recombinant polypeptide is produced by a method further comprising removing one or more new epitopes from at least one heterologous amino acid sequence derived from a second or additional species after the one or more new epitopes have been inserted into, joined to, engineered into, or replaced or substituted for a portion of the amino acid sequence of the polypeptide derived from a first species, - at least two or more different heterologous amino acid sequences or amino acid residues are inserted into, joined to, engineered into, or replace or substitute for a portion of the amino acid sequence of the polypeptide derived from a first species, optionally the at least two or more different heterologous amino acid sequences or amino acid residues are of different animal species, optionally at least one of the at least two or more different heterologous amino acid sequences or amino acid residues is derived from a human and at least one of the at least two or more different heterologous amino acid sequences or amino acid residues is derived from a non-human or animal species, for example as shown in FIG. 9; - at least one of the heterologous amino acid sequences or amino acid residues constitutes an artificial epitope not derived from at least the second species, for example as shown in FIG. 10; - at least one of the heterologous amino acid sequences or amino acid residues constitutes an epitope originally derived from at least a second species that is immunologically silent in the first species (not capable of generating an antibody response in the first species) but has been modified to become an immunologically active epitope capable of generating an antibody response thereagainst by the first species, for example as shown in FIG. 10; - at least one new epitope in the heterologous amino acid sequence or amino acid residues is modified such that antibodies generated by the first species against the modified new epitope bind weaker or slower than the equivalent unmodified new epitope, for example as shown in Figure 11; and / or - For example, as shown in Figure 12, the chimeric or recombinant polypeptide further comprises at least one new epitope from at least a second species that is not homologous to the first species and at least one new epitope against which antibodies can be generated in the first species.

[0011] In an alternative embodiment, a recombinant polypeptide is provided comprising a portion of a first polypeptide from a first species and at least a portion of a second polypeptide from a second species, wherein at least a portion of the second polypeptide is a homolog of the first polypeptide, and wherein at least a homologous portion of the second polypeptide comprises an epitope not present in the first polypeptide.

[0012] In an alternative embodiment of the recombinant polypeptide provided herein, - said portion of at least one second polypeptide is present at or substantially at the location of the homologous portion of the first polypeptide and replaces or substantially replaces the homologous portion of the first polypeptide; The recombinant polypeptide comprises at least a portion of a second polypeptide and at least a portion of a third polypeptide, each of which is a homolog of a different sequence of a first species, and the portion of the second polypeptide and the portion of the third polypeptide each comprise an epitope not present in the first polypeptide; - the first polypeptide and the second polypeptide have a similar, or substantially the same, 3D structure; - the first and second polypeptides have between about 25% and about 95% amino acid identity, or the first and second polypeptides have at least about 25% amino acid identity, or the first and second polypeptides have at least about 50% amino acid identity, or the first and second polypeptides have at least about 70% amino acid identity, or the first and second polypeptides have at least about 90% amino acid identity; - the first polypeptide and the second polypeptide have a Z-score of about 2 to about 8 when aligned using a distance matrix alignment, or the first polypeptide and the second polypeptide have a Z-score of at least 8 when aligned using a distance matrix alignment; - at least one sequence in the first polypeptide is removed and replaced by at least one epitope formed by a homologous portion of a second polypeptide, - at least one sequence removed from the first polypeptide comprises a sequence that is present in another member of the family to which the first and second polypeptides belong; - at least one of the removed sequences comprises a sequence that is present in a domain in another member of the family to which the first and second polypeptides belong, - at least one sequence is replaced by a sequence containing an epitope specifically recognized by a monoclonal antibody, - at least one replaced epitope is replaced by a sequence containing an epitope that provides at least one paratope (antigen binding site) subtype in the generated antibody, - at least one replaced epitope is replaced by a sequence that contains an epitope that is a dominant or more dominant epitope, - at least one replaced epitope is replaced by a sequence comprising an epitope that is a weak epitope, or a weaker epitope, or an epitope that elicits a weak humoral response in the first species, resulting in relatively low titers of antibodies, - in an alternative embodiment, one or more portions (or epitopes) of the sequence from the second species to be inserted into the polypeptide of the first species are first modified or altered to be identical or more similar to the sequence from the first species, thereby ensuring that only one or some of the epitopes originally or naturally present in the second sequence remain in the final recombinant or chimeric polypeptide, which may result in the polyclonal antibodies generated being more specific for the selected target (or epitope) (e.g. by reducing the number of epitopes present in the transferred second species) or may result in a change in the characteristics or properties of the polyclonal antibodies generated by eliminating the possibility of the presence of highly hydrophobic paratopes in the antibodies generated; - an epitope in the second polypeptide is modified to reduce the affinity of antibodies generated by the first species that specifically recognize said epitope compared to the unmodified epitope; - the recombinant polypeptide comprises a portion of a third polypeptide from a third species that comprises an epitope that is not present in either the first or second polypeptide, - at least one epitope present in another member of the family to which the first and second polypeptides belong is incorporated into the recombinant polypeptide, - at least one epitope present in a domain in another member of the family to which the first and second polypeptides belong is incorporated into the recombinant polypeptide; - the epitope from the second polypeptide is modified to increase the affinity of an antibody that specifically recognizes the epitope from the second polypeptide or to generate affinity for the epitope from the second polypeptide by an antibody that specifically recognizes said epitope, - the first species is rabbit and the second species is human, or the first polypeptide is a rabbit antibody light chain and the second polypeptide is a human antibody light chain, and / or - the recombinant polypeptide is administered to a first species, and the epitope is capable of eliciting the production of antibodies which specifically bind to the epitope in the second polypeptide but not to the first polypeptide.

[0013] In an alternative embodiment, recombinant nucleic acids are provided that encode the chimeric or recombinant polypeptides presented herein.

[0014] In an alternative embodiment of the recombinant nucleic acid provided herein, - a recombinant nucleic acid is or comprises a DNA or RNA molecule, where the RNA is an mRNA molecule, or the recombinant nucleic acid comprises synthetic or modified nucleotides which can be utilized by the cellular machinery to make a polypeptide; - the recombinant nucleic acid further comprises, and is operably linked to, a transcriptional regulatory element, optionally comprising a promoter, optionally wherein the promoter is an inducible promoter or a constitutive promoter; - the recombinant nucleic acid further comprises a sequence encoding an additional protein or peptide moiety or domain, - the additional protein or peptide moiety or domain comprises a purification moiety or domain that aids in the purification or isolation of the chimeric or recombinant antibody encoded by the recombinant nucleic acid, the additional protein or peptide moiety or domain comprises a histidine (poly-his) tag or a maltose binding protein; and / or - the recombinant nucleic acid further comprises a sequence encoding a protease cleavage site located between the purification moiety or domain and the sequence encoding the chimeric or recombinant antibody, optionally the protease cleavage site is a Tobacco Etch Virus (TEV) protease cleavage site.

[0015] In alternative embodiments, there are provided expression cassettes, vectors, recombinant viruses, artificial chromosomes, cosmids, or plasmids comprising the recombinant nucleic acids presented herein.

[0016] In alternative embodiments, a cell is provided that comprises a chimeric or recombinant polypeptide as presented herein, a recombinant nucleic acid as presented herein, or an expression cassette, vector, recombinant virus, artificial chromosome, cosmid, or plasmid as presented herein, optionally wherein the cell is a bacterial cell, a fungal cell, a mammalian cell, a yeast cell, an insect cell, or a plant cell.

[0017] In an alternative embodiment, there is provided a method for generating polyclonal antibodies or polyclonal immune sera specific for or specifically binding to an epitope, comprising the steps of: (a) administering to a subject or immunizing the subject thereby a chimeric or recombinant polypeptide presented herein; (b) administering to a subject a recombinant nucleic acid provided herein, or an expression cassette, vector, recombinant virus, artificial chromosome, cosmid, or plasmid provided herein; or (c) administering the cells provided herein to a subject. Including, Methods are provided wherein the subject is the species from which a first polypeptide presented herein is derived, or the subject is the species from which a portion of a first polypeptide presented herein is derived, and the epitope is from the species from which a second polypeptide presented herein is derived, or the epitope is from the species from which a portion of a second polypeptide presented herein is derived.

[0018] In an alternative embodiment of the method presented herein, - the subject is a mammal or avian species, or the subject is a rabbit, a murine species, a sheep, a goat, a pig, a cow, a horse, or a chicken, and optionally the murine species is a rat or a mouse; - the recombinant nucleic acid is an RNA or DNA construct, - the chimeric or recombinant polypeptide is produced by expressing in a cell a recombinant nucleic acid as provided herein, or an expression cassette, vector, recombinant virus, artificial chromosome, cosmid, or plasmid as provided herein, - the cell is a bacterial cell, a fungal cell, a mammalian cell, a yeast cell, an insect cell, or a plant cell; - the method further comprises substantially isolating or purifying the chimeric or recombinant polypeptide prior to administration to or immunization of the mammal, - the isolation or purification comprises the use of hydrophobic interaction chromatography (HIC), ion exchange chromatography (IEC), size exclusion chromatography (SEC), affinity purification, adsorption purification, or any combination thereof; - administration of steps (a), (b), or (c) is repeated 2 to 20 times, or repeated 2, 3, 4, 5, 6, 7, 8, 9, or 10 times, or repeated at intervals of 2 to 20 weeks or 3 to 16 weeks; - generating polyclonal antibodies or polyclonal immune sera that are substantially devoid of antibodies that are not specific or do not specifically bind to the epitope, - generating polyclonal antibodies or polyclonal immune sera that substantially comprise antibodies that are not specific or do not specifically bind to the epitope in the misfolded form, - at least one sequence in the first polypeptide is removed and replaced by an epitope formed by a portion of a second polypeptide, - at least one epitope in the sequence from the second polypeptide is replaced by an epitope present in another member of the family to which the first and second polypeptides belong, - at least one epitope in a sequence from the second polypeptide is replaced by a sequence comprising an epitope present in a domain in another member of the family to which the first and second polypeptides belong, - at least one epitope in the second polypeptide that is specifically recognized by the monoclonal antibody is replaced by a corresponding sequence from the first polypeptide, - at least one sequence in the second polypeptide that contains an epitope that results in (or generates) at least one paratope subtype is replaced with the corresponding sequence from the first polypeptide, - at least one sequence in the second polypeptide containing a dominant epitope is replaced by a corresponding sequence from the first polypeptide, - at least one sequence in the second polypeptide that contains a weak epitope or an epitope that elicits a weak humoral response resulting in relatively low titers of antibodies is replaced by the corresponding sequence from the first polypeptide, - the epitope in the second polypeptide is modified to reduce the affinity of an antibody that specifically recognizes said epitope, - the recombinant polypeptide comprises a portion of a third polypeptide from a third species that comprises an epitope that is not present in either the first or second polypeptide, - at least one epitope present in another member of the family to which the first and second polypeptides belong is incorporated into the recombinant polypeptide, - at least one epitope present in a domain in another member of the family to which the first and second polypeptides belong is incorporated into the recombinant polypeptide; and / or - the epitope from the second polypeptide is modified to increase the affinity of an antibody that specifically recognizes the epitope from the second polypeptide or to generate affinity for the epitope from the second polypeptide by an antibody that specifically recognizes said epitope.

[0019] In alternative embodiments, there is provided a chimeric or recombinant polypeptide as presented herein, a nucleic acid as presented herein, an expression cassette, a vector, a recombinant virus, an artificial chromosome, a cosmid, or a plasmid as presented herein, or a cell as presented herein for use in the generation of polyclonal antibodies or polyclonal immune sera that are specific or specifically bind to an epitope.

[0020] In alternative embodiments, there is provided the use of (a) a chimeric or recombinant polypeptide as presented herein, (b) a nucleic acid as presented herein, (c) an expression cassette, vector, recombinant virus, artificial chromosome, cosmid, or plasmid as presented herein, or (d) a cell as presented herein, for generating polyclonal antibodies or polyclonal immune sera that are specific or specifically bind to an epitope.

[0021] In alternative embodiments, chimeric or recombinant polypeptides are provided that include a ferritin polypeptide to which an immunogenic peptide or polypeptide is conjugated or attached by or through a substantially non-immunogenic linker, the immunogenic peptide or polypeptide comprising a chimeric or recombinant polypeptide provided herein, and the ferritin polypeptide being or derived from a first species. In alternative embodiments of these chimeric or recombinant polypeptides, - the ferritin polypeptide folds as a helical bundle that assembles into a ball-like structure containing 24 copies of the ferritin polypeptide; - the substantially non-immunogenic linker comprises a poly-G linker or a poly-(GGGGS) linker (SEQ ID NO: 31), optionally the poly-(GGGGS) linker (SEQ ID NO: 31) comprises or consists of a (GGGGS)5 (SEQ ID NO: 29) linker; - the ferritin polypeptide has at least one His(6)-Lys-His(3) (SEQ ID NO:32) site or a plurality of His(6)-Lys-His(3) (SEQ ID NO:32) sites; - the linker and / or one or more His(6)-Lys-His(3) sequences are optionally followed by a peptide or chimeric polypeptide carrying at least one epitope from a second species, for example human, - alternatively, the coiled-coil structural polypeptide is located after a linker and / or a His(6)-Lys-His(3) sequence, and this coiled-coil structural polypeptide can be linked to another coiled-coil structural polypeptide linked to an immunogenic moiety, peptide or chimeric polypeptide, both of which are derived from species 1 and are therefore non-immunogenic in species 1, - the first species is a non-human animal, optionally a mammal, optionally a rabbit, goat or llama, or the ferritin polypeptide is derived from a non-human animal, optionally a mammal, optionally a rabbit, goat or llama, and optionally the immunogenic peptide or polypeptide comprises a chimeric immunogenic peptide or polypeptide, which chimeric immunogenic peptide or polypeptide comprises a human immunogenic sequence inserted into a rabbit peptide or polypeptide, and the residue of the rabbit polypeptide is non-immunogenic when injected into a rabbit, and / or - the non-immunogenic rabbit peptide or polypeptide sequence is derived from a rabbit immunoglobulin polypeptide.

[0022] In an alternative embodiment of the chimeric or recombinant polypeptide provided herein, (a) the ferritin polypeptide comprises at least one first coiled-coil protein or motif capable of binding to a second coiled-coil protein or motif (optionally the second coiled-coil protein or motif comprises or is linked to an immunogenic peptide, which is optionally covalently linked by a non-immunogenic linker), and the first coiled-coil protein or motif is linked to the ferritin polypeptide by a non-immunogenic linker, resulting in a chimeric ferritin-coiled-coil protein polypeptide capable of optionally folding into a tertiary or helical bundle structure; Optionally, the coiled-coil protein or motif is derived from a first species, and optionally the coiled-coil protein or motif derived from the first species binds to another coiled-coil protein or motif derived from the first species; Optionally, the ferritin polypeptide comprises two, three, four or more first coiled-coil proteins or motifs, Optionally, the coiled-coil protein or motif comprises gamma-aminobutyric acid type B receptor subunit 1 isoform X1 (GBR1) and / or gamma-aminobutyric acid type B receptor subunit 2 (GBR2), wherein GBR1 can selectively bind to the GBR2 motif; Optionally, the GBR1 motif is STNNNEEEKSRLLEKENRELEKIIAEKEERVSELRHQLQSR (SEQ ID NO: 33), Optionally, the GBR2 motif is SVNQASTSRLEGLQSENHRLRMKITELDKDLEEVTMQLQDT (SEQ ID NO:34), (b) the amino acid sequence of the ferritin polypeptide has at least one His(6)-Lys-His(3) (SEQ ID NO:32) site or multiple His(6)-Lys-His(3) (SEQ ID NO:32) sites inserted therein; (c) the substantially non-immunogenic linker comprises a poly-G linker or a poly-(GGGGS) linker (SEQ ID NO: 31); (d) the poly-(GGGGS) linker (SEQ ID NO:31) comprises or consists of a (GGGGS)5 (SEQ ID NO:29) linker; (e) the non-immunogenic linker is attached to the amino terminus of the ferritin polypeptide; (f) the first species is rabbit or the ferritin polypeptide is derived from rabbit; (g) the immunogenic peptide or polypeptide comprises a chimeric immunogenic peptide or polypeptide, which comprises a human immunogenic sequence inserted into a rabbit peptide or polypeptide, the residues of the rabbit polypeptide being non-immunogenic when injected into a rabbit; and / or (h) The non-immunogenic rabbit peptide or polypeptide sequence is derived from a rabbit immunoglobulin polypeptide.

[0023] In an alternative embodiment, an article of manufacture is provided that comprises a plurality of the chimeric or recombinant polypeptides presented herein, Optionally, the article of manufacture comprises 24 chimeric or recombinant polypeptides; Optionally, each of the chimeric or recombinant polypeptides comprises a coiled-coil protein, and the coiled-coil proteins bind to each other.

[0024] In an alternative embodiment, a method of generating an epitope-specific antibody response in a rabbit is provided, the immune response comprising the generation of rabbit antibodies specific for (or specifically binding to) at least one human epitope, the method comprising administering to the rabbit a chimeric or recombinant polypeptide as presented herein in an amount sufficient to generate the epitope-specific antibody response.

[0025] The details of one or more exemplary embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.

[0026] All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.

[0027] The patent or application contains at least one drawing executed in color. Copies of this patent or patent application publication containing color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

[0028] The drawings described herein are illustrative of exemplary embodiments presented herein and are not intended to limit the scope of the invention as contained in the claims. [Brief description of the drawings]

[0029] [Figure 1A] Figure 1 shows the transfer of human epitopes to a rabbit scaffold.Figure 1 shows a sequence alignment of human (SEQ ID NO:2) and rabbit (SEQ ID NO:1) λLC constant domain sequences, where sequence differences were found using sequence alignment. [Figure 1B] Figure 1 shows the transfer of human epitopes to a rabbit scaffold. Schematic representation of selected epitopes including species-specific sequences located within selected cryptic regions. [Figure 1C] Figure 13: Transfer of human epitopes onto a rabbit scaffold. Shown are the chimeric sequences of rhLAC1 (SEQ ID NO:3), rhLAC2+3 (SEQ ID NO:4), and rhLAC7 (SEQ ID NO:5) in which selected epitopes (black, underlined and bold) were grafted onto rabbit backbone sequences (teal), which were synthesized and inserted into expression vectors as described in detail in Example 1 below. [Figure 2A]The expression construct was transformed into cells from an appropriate organism and used for production of the chimeric protein. An image showing expression of the chimeric protein. The protein was purified using standard methods such as HIS capture and size exclusion columns, and protein expression was confirmed by SDS-PAGE demonstrating overexpression of the protein at the expected band of approximately 13-14 kDa. An SDS-PAGE page image is shown. [Figure 2B] The expression constructs were transformed into cells from the appropriate organism and used for production of the chimeric protein. An image showing expression of the chimeric protein is shown. An SDS-PAGE image showing purity after TEV cleavage is shown. [Figure 2C] The expression constructs were transformed into cells from the appropriate organism and used for production of the chimeric protein. Images showing expression of the chimeric protein. Western blot images showing purity after TEV cleavage are shown. A positive control containing E. coli impurities was included (lane labeled 1) to demonstrate functionality of the anti-E. coli pAb used to check sample purity in the Western blot. [Diagram 3] FIG. 3 graphically depicts data showing that human epitopes inserted into a rabbit backbone can be specifically recognized by antibodies raised against native human lambda free light chain (hλ-FLC, variable and constant domains). ELISA plates were coated with the chimeric λ-LC constant domains (rh-λ-LC-CD) rhLac1 (FIG. 3A), rhLac2+3 (FIG. 3B), and rhLac7 (FIG. 3C), or the rabbit λ-LC constant domain rLac (FIG. 3D). DAKO A0101 (rabbit polyclonal anti-human λ-FLC antibody, red line) was used as the primary antibody, followed by a secondary HRP-conjugated goat polyclonal anti-rabbit IgG antibody reagent (P0448) with TMB as the colorant in a standard procedure. [Figure 4]Figure 4 graphically depicts data showing that polyclonal antibodies (pAbs) elicited by immunization with chimeric lambda light chain constant domain (λ-LC-CD) are specific for human λ-LC. Purified chimeric proteins bearing human epitopes on rabbit λ-LC-CD scaffolds were used for immunization of rabbits. Antisera were collected and Ig fractions were purified. The pAbs (blue lines) were used as primary antibodies in standard ELISA assays described in Figure 3. Figure 4A-C shows that wells coated with 1 μg / mL of chimeric λ-LC-CD rhLAC1 (Figure 4A), rhLAC2+3 (Figure 4B), and rhLAC7 (Figure 4C) were recognized by this primary antibody, indicating that the chimeric proteins induce the rabbit immune system to elicit pAbs against selected epitopes in the human λ-LC protein. This was further supported by the fact that wells coated with rabbit λ-LC (Figure 4D) were not recognized by the pAb, whereas wells coated with 1 μg / mL human λ-LC (variable and constant domains) (Figure 4E) were also recognized by the pAb, again indicating that chimeric λ-LC-CD can induce pAbs against native human λ-LC. [Diagram 5] Schematic diagram of human IgG molecule, showing that it consists of two heavy chains (grey) and two light chains (colored). There are two variants of light chains, kappa and lambda. Both contain a variable domain (blue) and a constant domain (red). The interaction between the complete heavy and light chains (intact IgG, where both heavy and light chains are paired together) masks a part of the light chain. The part of the light chain that is masked is called the "hidden surface" and the rest is called the "exposed surface". [Figure 6] Sequence alignment and 3D structure of the human (SEQ ID NO: 6) and rabbit (SEQ ID NO: 7) lambda light chain constant domain. The domain has a beta sandwich made up of two paired beta sheets. The red sheet is made up of four beta strands, the blue sheet is made up of three beta strands, and the red beta strands make up the hidden surface. [Figure 7] FIG. 1 is a schematic diagram of an exemplary process for preparing an immunogen (or antigen) presented herein to generate antibodies or polyclonal antibodies, where the immunogen generates polyclonal antibodies against one or more epitopes of one species inserted into a protein, optionally a homologous protein, from a second species, and the polyclonal antibodies are made in the second species. [Figure 8] FIG. 1 is a schematic diagram illustrating an exemplary process for preparing an immunogen (or antigen) presented herein to generate antibodies or polyclonal antibodies, where the immunogen is engineered or designed to lack one or more epitopes, such that when the immunogen is used to generate polyclonal antibodies, no antibodies are generated against the removed epitope or epitopes. [Figure 9] FIG. 1 is a schematic diagram illustrating an exemplary process for preparing an immunogen (or antigen) presented herein to generate antibodies or polyclonal antibodies, where the immunogen is engineered or designed to contain one or more additional epitopes, such that when the immunogen is used to generate polyclonal antibodies, antibodies specific for the one or more additional epitopes are generated. [Figure 10] FIG. 1 is a schematic diagram illustrating an exemplary process for preparing an immunogen (or antigen) presented herein to generate antibodies or polyclonal antibodies, where the immunogen is engineered or designed to contain one or more modified epitopes which, in their unmodified form, do not generate an immune response in a second species, but which, in their modified form, do generate an immune response in a second species. [Figure 11]FIG. 1 is a schematic diagram illustrating an exemplary process for preparing an immunogen (or antigen) presented herein for generating antibodies or polyclonal antibodies, where the immunogen is engineered or designed to contain one or more modified epitopes, which epitopes are modified to be less immunogenic, such that when the immunogen is used to generate polyclonal antibodies, a less robust immune response is generated, or the polyclonal antibodies generated bind relatively weakly or slowly to proteins bearing the modified epitope(s). [Figure 12] FIG. 1 shows a schematic of an exemplary process for preparing the immunogens (or antigens) presented herein for generating antibodies or polyclonal antibodies. [Figure 13] FIG. 1 shows the transfer of human epitopes to a rabbit scaffold; in particular, the figure shows a chimeric λ-LC-CD (SEQ ID NO: 8) displaying selected epitopes (black, or bold) (see also FIG. 1A showing sequence alignment of human (SEQ ID NO: 2) and rabbit (SEQ ID NO: 1) λ-LC constant domain sequences, where sequence differences were found using sequence alignment). [Figure 14] 1 is an image of a λ-LC-CD; the image on the left shows human epitopes (lighter shading, or yellow) grafted onto a rabbit backbone (dark teal) sequence, as further described in Example 2 below. [Figure 15] 1 is an SDS-PAGE image showing purity after TEV cleavage, as further described in Example 2 below. [Figure 16] 1A-1D are SDS-PAGE and Western blotting images showing purity after TEV and SEC purification, as further described in Example 2 below. [Figure 17]FIG. 1 graphically depicts data showing that polyclonal antibodies (pAbs) elicited by immunization with refined chimeric lambda free light chain (λ-LC) constant domains are specific for the cryptic surface of human λ-LC. Purified chimeric proteins bearing human epitopes on a rabbit λ-LC-CD scaffold were used for immunization of rabbits. Antisera were collected and the Ig fraction was purified (IgGfexample2). pAbs (IgGfexample1, solid line, or blue line; A0101, intermittent dashed line (----), or red line; and IgGfexample2, dotted line (...), or yellow line) were used as primary antibodies in standard ELISA assays or agglutination assays as described in FIG. 3. FIG. 17A shows that wells coated with 1 μg / mL (6.67 μM) SEC-purified human IgG were recognized by IgGfexample1 and A0101, whereas IgGfexample2 had significantly lower reactivity to intact human IgG, indicating that IgGfexample1 and A0101 contain specific paratopes on the exposed surface; FIG. 17B shows that only IgGfexample1 contains the property to aggregate in the presence of intact human IgG; the positive control in FIG. 17C shows that all pAbs aggregate in the presence of human λ-FLC; and the negative control in FIG. 17D shows that IgGfexample1 and IgGfexample2 are unable to aggregate in the presence of rabbit IgG, thus supporting the ELISA data from FIG. 4D and also showing that chimeric λ-LC-CD can elicit pAbs against native human λ-FLC. [Figure 18] Figure 18 shows the transfer of human epitopes to a rabbit scaffold: Figure 18A shows the sequence differences between human and rabbit serum amyloid A (SAA) found using sequence alignment, with the human sequence as SEQ ID NO: 9 and the rabbit sequence as SEQ ID NO: 10, and Figure 18B shows the chimeric serum amyloid A (SAA) sequence (SEQ ID NO: 11) and shows selected epitopes (black, underlined and bold) that include species-specific sequences located within hydrophilic regions that were grafted into the rabbit backbone (red) sequence. [Figure 19] 1 is an image of SAA, the image on the left shows human epitopes (lighter shading, or yellow) grafted onto a rabbit backbone (red) sequence, as further described in Example 3 below. [Figure 20] Figure 20 shows the transfer of human epitopes to a rabbit scaffold: Figure 20A shows how sequence differences between human (SEQ ID NO: 12) and rabbit (SEQ ID NO: 13) kappa light chain constant domains (κ-LC-CD) were found using sequence alignment, as further described in Example 4 below, and Figure 20B shows a chimeric sequence (SEQ ID NO: 14) in which selected kappa light chain (κ-LC) epitopes (black, underlined and bold) were grafted onto the rabbit backbone (blue) sequence. [Figure 21] FIG. 1 shows selected kappa light chain (κ-LC) CD epitopes (lighter shading, or yellow, in the image on the left); these epitopes were species-specific sequences located within selected cryptic regions, as further described in Example 4 below. [Figure 22] Figure 22A shows an SDS-PAGE showing protein expression to demonstrate overexpression of kappa light chain constant domain (κ-LC-CD) protein at the expected band of approximately 13-14 kDa (arrow) in both pellet (P) and supernatant (S), as further described in Example 4 below. Figure 22B shows an SDS-PAGE showing chimeric (κ-LC-CD) protein purity after TEV cleavage and SEC, as further described in Example 4 below. Figure 22C shows a Western blot (WB) showing chimeric κ-LC-CD protein purity after TEV cleavage and SEC, as further described in Example 4 below. [Diagram 23]Figure 23A is a diagram of wells coated with SEC-purified human IgG at 1 μg / mL (6.67 nM). The positive control Q0499 (dotted line (...), or light blue line) strongly recognized intact human IgG, whereas the negative control A0100 (intermittent dashed line (-----), or red line) showed poor binding and antiserum against the chimera (κ-LC-CD, solid line, or yellow line) had little reactivity. This demonstrates that the chimeric antigen generates little, if any, side-reactivity against intact human IgG. Figure 23B is a diagram of wells coated with native human κLC (variable and constant domains) at 1 μg / mL (40 nM). The two negative controls A0499 (lower dotted line, or light blue) and A0101 (lower intermittent dashed line (-----), or red line) did not react with human κ-LC, whereas the positive control A0100 (upper intermittent dashed line (-----), or red / orange line) and the antiserum from a rabbit immunized with chimeric κ-LC-CD (solid line, or yellow line) both yielded strong signals. This demonstrates that the chimeric constant domain induces an immune response against an epitope present in native human κ FLC. Figure 23C is a picture of wells coated with 1 μg / mL (80 nM) chimeric κ-LC-CD. The anti-rabbit IgG antibody-HRP visualization reagent gave high background, while no signal was detectable using the negative controls Q0499 (dotted or light blue line) and A0101 (intermittent dashed-dotted (-.-), or red / gray line), and the positive control A0100 (dashed (---), or solid, or red / orange line) gave a signal above background, and to an even greater extent with antisera from rabbits immunized with chimeric κ-LC-CD. This demonstrates that both antisera and A0100 recognized chimeric κ-LC-CD. Figure 23D is an image of wells coated with 1 μg / mL (80 nM) of recombinant rabbit kappa LC constant domain r-κ-LC-CD.All binding of antisera to κ-LC-CD was below background, in contrast to the high levels of binding to the chimeric constant domain (FIG. 23C), indicating that the polyclonal antibodies in the antisera were specific for the human epitopes inserted into the rabbit scaffold. [Figure 24] FIG. 24A shows an agglutination experiment with SEC-purified human IgG at 1 mg / mL (6.67 μM). The positive control Q0499 (light blue) strongly agglutinates intact human IgG, whereas the negative control A0100 (red) and antiserum against chimeric κ-LC-CD (yellow) fail to agglutinate. This, together with the ELISA data from FIG. 23A, indicates that the chimeric antigen generates little, if any, side reactivity against intact human IgG. FIG. 24B shows an agglutination experiment with SEC-purified rabbit IgG at 1 mg / mL (6.67 μM). No agglutination is observed with A0499 (dotted, or light blue line), A0100 (dashed (---) or red / orange line), or antiserum from rabbits immunized with chimeric κ-LC-CD (solid, or yellow line). This demonstrates that the chimeric constant domain does not induce an immune response against self (rabbit) sequences. FIG. 24C shows an agglutination experiment with native human κ FLC at 1 mg / mL (40 μM). Agglutination is observed for A0100 (dashed or red line) and for antiserum from rabbits immunized with chimeric κ-LC-CD (solid or yellow line). This confirms that the inserted human epitope induces an immune response against the native human antigen. FIG. 24D shows an agglutination experiment with chimeric κ-LC-CD at 1 mg / mL (80 μM). Both antiserum (solid or yellow line) and A0100 (dashed or red line) agglutinate with chimeric κ-LC-CD, indicating that the applied epitope can be bound by more than one antibody. In turn, this indicates that at least two antibodies can bind simultaneously to a hidden surface. [Figure 25A]FIG. 1 shows how sequence alignment was used to discover sequence differences between human and rabbit gamma immunoglobulins (IgG). As further described in Example 5 below, chimeric sequences containing selected epitopes (colored and underlined) were grafted into rabbit backbone sequences, synthesized, and inserted into expression vectors; rabbit backbone (SEQ ID NO: 15); rhIgG1 (SEQ ID NO: 16); rhIgG2 (SEQ ID NO: 17); rhIgG2_2 (SEQ ID NO: 18); rhIgG3 (SEQ ID NO: 19); rhIgG4 (SEQ ID NO: 20). [Figure 25B] FIG. 1 shows how sequence alignment was used to discover sequence differences between human and rabbit gamma immunoglobulins (IgG). As further described in Example 5 below, chimeric sequences containing selected epitopes (colored and underlined) were grafted into rabbit backbone sequences, synthesized, and inserted into expression vectors; rabbit backbone (SEQ ID NO: 15); rhIgG1 (SEQ ID NO: 16); rhIgG2 (SEQ ID NO: 17); rhIgG2_2 (SEQ ID NO: 18); rhIgG3 (SEQ ID NO: 19); rhIgG4 (SEQ ID NO: 20). [Figure 25C] FIG. 1 shows how sequence alignment was used to discover sequence differences between human and rabbit gamma immunoglobulins (IgG). As further described in Example 5 below, chimeric sequences containing selected epitopes (underlined and bold) were grafted into rabbit backbone sequences, synthesized, and inserted into expression vectors; rabbit backbone (SEQ ID NO: 15); rhIgG1 (SEQ ID NO: 16); rhIgG2 (SEQ ID NO: 17); rhIgG2_2 (SEQ ID NO: 18); rhIgG3 (SEQ ID NO: 19); rhIgG4 (SEQ ID NO: 20). [Figure 25D]FIG. 1 shows how sequence alignment was used to discover sequence differences between human and rabbit gamma immunoglobulins (IgG). As further described in Example 5 below, chimeric sequences containing selected epitopes (underlined and bold) were grafted into rabbit backbone sequences, synthesized, and inserted into expression vectors; rabbit backbone (SEQ ID NO: 15); rhIgG1 (SEQ ID NO: 16); rhIgG2 (SEQ ID NO: 17); rhIgG2_2 (SEQ ID NO: 18); rhIgG3 (SEQ ID NO: 19); rhIgG4 (SEQ ID NO: 20). [Figure 26A] 1 shows rabbit IgG and a chimeric IgG made by the methods presented herein in which human isotype-specific epitopes (colored or darker than the gray IgG backbone) have been grafted onto a rabbit IgG backbone (gray). Shown is a rabbit IgG backbone without any human epitopes inserted, as further described in Example 4 below. [Figure 26B] 1 shows rabbit IgG and chimeric IgG produced by the methods presented herein in which human isotype-specific epitopes (colored or darker than the gray IgG backbone) have been grafted onto a rabbit IgG backbone (gray). Shown is a chimeric IgG1 subtype with an inserted human epitope (colored or darker), as further described in Example 4 below. [Figure 26C] 1 shows rabbit IgG and chimeric IgG produced by the methods presented herein in which human isotype-specific epitopes (colored or darker than the gray IgG backbone) have been grafted onto a rabbit IgG backbone (gray). Shown is a chimeric IgG2 subtype containing an inserted human epitope (colored or darker), as further described in Example 4 below. [Figure 26D]1 shows rabbit IgG and a chimeric IgG made by the methods presented herein in which human isotype-specific epitopes (colored or darker than the gray IgG backbone) have been grafted onto a rabbit IgG backbone (gray). Shown is the chimeric IgG2_2 subtype with inserted human epitopes (colored or darker), as further described in Example 4 below. [Figure 26E] 1 shows rabbit IgG and chimeric IgG produced by the methods presented herein in which human isotype-specific epitopes (colored or darker than the gray IgG backbone) have been grafted onto a rabbit IgG backbone (gray). Shown is a chimeric IgG3 subtype containing an inserted human epitope (colored or darker), as further described in Example 4 below. [Figure 26F] 1 shows rabbit IgG and chimeric IgG produced by the methods presented herein in which human isotype-specific epitopes (colored or darker than the gray IgG backbone) have been grafted onto a rabbit IgG backbone (gray). Shown is a chimeric IgG4 subtype containing an inserted human epitope (colored or darker), as further described in Example 4 below. [Figure 27A]

[0023] Figure 1 shows data demonstrating how anti-human epitope specific responses can be generated by substituting human epitopes onto a non-human polypeptide background. Shown are rabbit IgGs engineered with (or inserted into) epitopes specific for human IgG1, IgG2, IgG3, and IgG4, as described in detail in Example 6 below. [Figure 27B] 1 shows data demonstrating how an anti-human epitope specific response can be generated by placing a human epitope onto a non-human polypeptide background. 2 shows a graphical representation of data showing rabbit immune responses to human IgG1 epitopes in rabbit Igs, as described in detail in Example 6 below. [Figure 27C]1 shows data demonstrating how an anti-human epitope specific response can be generated by placing a human epitope onto a non-human polypeptide background. 2 shows a graphical representation of data showing rabbit immune responses to human IgG2 epitopes in rabbit Igs, as described in detail in Example 6 below. [Figure 27D] 1 shows data demonstrating how an anti-human epitope specific response can be generated by placing a human epitope onto a non-human polypeptide background. 2 shows a graphical representation of data showing rabbit immune responses to human IgG3 epitopes in rabbit Igs, as described in detail in Example 6 below. [Figure 27E] Figure 1 shows data demonstrating how an anti-human epitope specific response can be generated by placing a human epitope onto a non-human polypeptide background.Figure 2 graphically depicts data showing rabbit immune responses to human IgG4 epitopes in rabbit Igs, as described in detail in Example 6 below. [Figure 27F] Figure 1 shows data demonstrating how anti-human epitope specific responses can be generated by placing human epitopes onto a non-human polypeptide background. Shown are IgG1 or IgG2 subtypes redesigned to improve rabbit reactivity to Ig1 and IgG2 epitopes, as described in detail in Example 6 below, where SEQ ID NO: 21 is the rabbit backbone, SEQ ID NO: 22 is rhlgG1_2, and SEQ ID NO: 23 is rhlgG2_3. [Figure 28]28A-28D show the construction of chimeric antibodies with desired properties. As described in detail in Example 7 below, FIG. 28A shows the rabbit serum amyloid A (SAA) backbone, with the red residues (or darker colors) being the rabbit SAA sequence and the lighter shaded or yellow residues representing inserted human specific amino acids, FIG. 28B shows human SAA, with the blue (or darker colors) showing six hydrophobic residues that may interact with lipid surfaces, FIG. 28C shows the antibodies derived from immunization with SAA shown in FIG. 28A coupled to beads, FIG. 28D shows that antibodies derived from immunization with SAA as shown in FIG. 28B result in immune particles with antibodies (Abs) containing several paratopes that recognize human hydrophobic (blue) epitopes, and FIG. 28E-F show the kinetics of C and D responding to five different levels of SAA. [Figure 29] FIG. 1 graphically depicts data showing that immunization with incompletely human epitopes can result in slow-reactive polyclonal antibodies (srpAb) against human C-reactive protein (CRP), as described in detail in Example 8 below. [Diagram 30] FIG. 30A shows an exemplary chimeric ferritin construct containing linked immunoglobulin antigen CDv6, as described in detail in Example 9 below, with CDv6 shown separately in FIG. 30B. [Diagram 31] FIG. 11 is an image of a Western blot showing that a pAb (sample 1108) used as primary IgG raised against the immunogen CdV6, a chimeric rabbit-human free light chain domain, interacts with B9 (columns #2 and #1 are different purified fractions) and the "20 fraction" from size exclusion, as described in detail in Example 9 below. [Diagram 32] FIG. 1 is a graphical representation of data showing dynamic light scattering (DLS), or size distribution by intensity (size as a function of intensity), as described in detail in Example 9 below. [Diagram 33]FIG. 13 graphically depicts data demonstrating that CDv6 expressed fused to ferritin is properly folded, as described in detail in Example 9 below. [Diagram 34] FIG. 34A shows the sequence of an exemplary recombinant ferritin core (SEQ ID NO:35) presenting (or including) a modified CdV6 with a human epitope inserted therein, as described in detail in Example 9 below. The partial sequence is: [ka] Figure 34B (SEQ ID NO:36) shows a heterodimer formed by non-covalent binding of (1) a chimeric recombinant antigen, which is covalently linked to the amino terminus of a coiled-coil GBR2 motif (SEQ ID NO:34), to (2) a GBR1 motif (underlined) (SEQ ID NO:33) linked to the amino terminus of a ferritin molecule by the use of a non-immunogenic linker (bold) (SEQ ID NO:29), the two subunits of which are non-covalently linked by the bond between the GBR1 and GBR2 motifs, i.e. [ka] FIG. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0030] Like reference numbers in the various drawings indicate like elements.

[0031] In an alternative embodiment, chimeric immunogens and methods for making and using them are provided, including methods for obtaining polyclonal antibodies specific for selected epitopes.

[0032] In an alternative embodiment, a method is provided that includes immunizing an animal with a chimeric or recombinant immunogen as presented herein, e.g., the animal is immunized with a modified version, or portion thereof, of one of the naturally occurring proteins bearing a selected epitope from a protein of another type of animal or species, e.g., a homologous protein, and the artificial hybrid protein or protein domain, i.e., the chimeric or recombinant immunogen as presented herein, causes the animal to produce polyclonal antibodies specific for one or more selected epitopes from the protein of the other type of animal or species.

[0033] In an alternative embodiment, an exemplary process for preparing an immunogen (or antigen) presented herein to generate antibodies or polyclonal antibodies, as shown in FIG. 7, is provided, where the immunogen generates polyclonal antibodies against one or more epitopes of one species inserted into a protein, optionally a homologous protein, from a second species, and the polyclonal antibodies are made in the second species.

[0034] In an alternative embodiment, as shown in FIG. 8, an exemplary process for preparing an immunogen (or antigen) presented herein to generate antibodies or polyclonal antibodies is provided, where the immunogen is engineered or designed to lack one or more epitopes, such that when the immunogen is used to generate polyclonal antibodies, no antibodies are generated against the removed epitope or epitopes.

[0035] In an alternative embodiment, an exemplary process for preparing an immunogen (or antigen) presented herein to generate antibodies or polyclonal antibodies, as shown in FIG. 9, is provided, where the immunogen is engineered or designed to contain one or more additional epitopes, such that when the immunogen is used to generate polyclonal antibodies, antibodies specific for the one or more additional epitopes are generated.

[0036] In an alternative embodiment, an exemplary process for preparing an immunogen (or antigen) presented herein to generate antibodies or polyclonal antibodies, as shown in FIG. 10, is provided, where the immunogen is engineered or designed to contain one or more modified epitopes which, in their unmodified form, do not generate an immune response in a second species, but which, in their modified form, do generate an immune response in the second species.

[0037] In an alternative embodiment, an exemplary process for preparing an immunogen (or antigen) presented herein for generating antibodies or polyclonal antibodies, as shown in FIG. 11, is provided, where the immunogen is engineered or designed to contain one or more modified epitopes, which epitopes or epitopes are modified to be less immunogenic, such that when the immunogen is used to generate polyclonal antibodies, a less robust immune response is generated, or the generated polyclonal antibodies bind relatively weakly or slowly to proteins bearing the one or more modified epitopes.

[0038] In an alternative embodiment, an exemplary process for preparing the immunogens (or antigens) presented herein for generating antibodies or polyclonal antibodies is provided, as shown in FIG.

[0039] Chimeric or Recombinant Polypeptides and Nucleic Acids In alternative embodiments, chimeric or recombinant polypeptides and methods of making and using them are provided. In alternative embodiments, chimeric or recombinant nucleic acids that encode and express the polypeptides presented herein are provided, including expression vehicles that contain and express these nucleic acids, and cells that contain and express these nucleic acids, including whole organism expression systems.

[0040] In alternative embodiments, the recombinant polypeptides provided herein can be prepared and expressed using any method known in the art, including, for example, the use of whole organisms, such as fungi, plants, or animals, such as mice, and cell cultures derived from whole organisms (e.g., mammalian cells in culture), or the use of unicellular organisms, such as algae, fungi, yeast, insect (e.g., baculovirus) or bacterial cells.

[0041] The choice of organism for making (e.g., recombinantly producing) the chimeric or recombinant polypeptides and / or nucleic acids presented herein may depend on several factors, including whether secondary modifications such as glycosylation are desired or required, or whether it is desired or required for the protein to be attached to or inserted into a membrane system (e.g., in situ), or whether a particular protein folding pattern is desired or required, and / or whether disulfide bridge formation is desired or required.

[0042] In an alternative embodiment, the nucleic acid for expressing the chimeric or recombinant polypeptide presented herein, for example for in vitro or in vivo expression, is contained in an expression vehicle, for example, an expression cassette, vector, recombinant virus, artificial chromosome, cosmid, or plasmid.In an alternative embodiment, the nucleic acid or expression vehicle expressing the chimeric or recombinant polypeptide presented herein is administered to an animal (for example, as naked DNA, which can be appropriately formulated) for the purpose of making the animal generate a humoral immune response against the epitope in the recombinant polypeptide presented herein.

[0043] In alternative embodiments, the protein-encoding DNA sequence, which may be present in the expression vehicle, is transferred to an organism or cell and placed under the control of appropriate expression elements, such as a transcription promoter, enhancer, and / or polyadenylation signal sequence. In alternative embodiments, the protein sequences presented herein are processed in specific cellular organelles, which may require the addition of one or more localization signals, such as a periplasmic localization sequence.

[0044] In alternative embodiments, the protein-encoding DNA sequence (e.g., as an expression vehicle) may be inserted into the genome (either stably or not) or alternatively may be episomal. Recombinant protein expression systems may be transient or permanent.

[0045] In alternative embodiments, recombinantly produced proteins are purified, for example to enhance the ability of a given protein to act or function as an antigen or immunogen for immunization purposes, for example, the presence of impurities can result in immunized animals making antibodies against unrelated targets, the presence of excess impurities can abolish the formation of large amounts of desired antibodies, and sterilizing polyclonal antibodies from reactivity to impurities can be time-consuming and costly.

[0046] In alternative embodiments, purification of protein species is based on specific characteristics of the desired protein, for example, purification includes using hydrophobicity, charge, and / or size using chromatographic means such as hydrophobic interaction chromatography (HIC), ion exchange chromatography (IEC), and / or size exclusion chromatography (SEC). In alternative embodiments, specific protein interactions are used for purification purposes, for example, affinity purification is used, or the lack of specificity of the protein is used to remove other protein species, for example, absorption purification is used. In alternative embodiments, antibodies or other protein-specific binding proteins are used for affinity and / or absorption purification of proteins.

[0047] In alternative embodiments, proteins are recombinantly expressed with the addition of protein sequences that allow for specific purification methods, such as epitope tags, such as FLAG, hemagglutinin (HA), c-myc, T7, Glu-Glu, ALFA-tag, V5-tag, Myc-tag, HA-tag, Spot-tag, T7-tag, and NE-tag; biotin and streptavidin or avidin systems; polyhistidine affinity tags, such as small HIS-tags (6-8 amino acids) (optionally using immobilized metal affinity chromatography); an N-terminal glutathione S-transferase (GST) molecule followed by a protease cleavage site; the large 43 kDa maltose binding protein (MBP); an intein-chitin binding domain (intein-CBD) tag; or the calmodulin-binding peptide (CBP) purification system, which utilizes a C-terminal fragment of muscle myosin light chain kinase to purify the protein of interest from bacteria. This increases the number of tools available for purification purposes and allows standard methods to be used for many different proteins.

[0048] In some cases, it is desirable to remove such purification sequences before immunization. This can be achieved by placing a protease site between the purification sequence and the actual protein coding sequence, such as the sequence of the chimeric protein presented herein. One example is the tobacco etch virus (TEV) protease, which leaves only an N-terminal glycine residue upon cleavage of the consensus sequence.

[0049] In an alternative embodiment, the recombinant proteins presented herein are made in situ in the immunized animal, e.g., by modifying the cells of the animal to carry new or altered DNA sequences capable of coding for the expression of the recombinant proteins, and expressing and / or secreting these immunogenic proteins.

[0050] Immunization process In an alternative embodiment, a method of producing antibodies or generating or stimulating an immune response in an animal, e.g., a mammal (e.g., a rabbit, a murine species such as a mouse or rat, a sheep, a goat, a pig, a cow, or a horse), or in a pheasant species (e.g., a chicken), is provided, comprising administering a chimeric or recombinant protein presented herein.

[0051] In an alternative embodiment, proteins from one type of animal (species) are used to generate an immune response in another type of animal (species) to elicit polyclonal antibodies against a protein target.

[0052] In an alternative embodiment, a chimeric or recombinant protein presented herein comprising at least one human epitope is used to generate a humoral response in, for example, a mouse, rat, rabbit, sheep, goat, pig, cow, horse, or chicken for stimulation of the immune system, and one or more polyclonal antibodies derived or generated can specifically recognize the human protein and can be used to specifically recognize, tag, bind to, and / or isolate the human protein from which the at least one human epitope is derived.

[0053] In alternative embodiments, a protein from any species is used to immunize another species to generate a humoral immune system, so long as the protein used for immunization has at least one modification (e.g., at least one single amino acid difference) compared to any homologous protein or protein domain in the species being immunized.

[0054] In an alternative embodiment, an adjuvant is also used when administering the chimeric or recombinant protein presented herein. The administered chimeric or recombinant protein is an agent that induces an immune response to generate antibodies against the specific epitope expressed by the recombinant protein, while the adjuvant mixed with the protein can ensure that the immune system is activated. For example, by using an adjuvant, the protein is placed in a depot that is released in the body for a longer period of time. In an alternative embodiment, various adjuvants are used, for example, adjuvants based on various principles such as the oil-in-water principle, for example Freund's adjuvant. In an alternative embodiment, the mixture of protein and adjuvant is injected into one or more subcutaneous sites. In an alternative embodiment, the administration step is repeated several times (e.g., about 2 to 10 times) to boost the immune response (boost phase). Also, the mass production of polyclonal antibodies can be maintained by renewing the immunization with booster doses at regular but typically longer intervals, for example, once every 3 to 16 weeks.

[0055] Selection of epitopes for grafting into protein backbones In an alternative embodiment, a recombinant polypeptide is provided that comprises a portion of a first polypeptide from a first species and at least a portion of a second polypeptide from a second species, where at least a portion of the second polypeptide is a homolog of the first polypeptide, and the homologous portion of the second polypeptide comprises an epitope that is not present in the first polypeptide. In an alternative embodiment, the homologous protein or protein domain is present in two species of interest.

[0056] In an alternative embodiment, homologous proteins are proteins with similar 3D structures. If multiple proteins have more than 30% identical protein sequence similarity, they will have the same 3-D structure in 90% of cases, and even multiple proteins with significantly lower sequence identity may have similar 3-dimensional structures. In an alternative embodiment, the similarity of 3-D structures between proteins is evaluated, for example, using distance matrix alignment (DALI), and as a guide, a Z score of more than 8 indicates homology, while a score of 2 to 8 represents a gray zone.

[0057] In an alternative embodiment, the backbone protein, or first polypeptide from a first species, is derived from the species to be immunized (species 1) and the epitope sequence is derived from the species to be recognized by a polyclonal antibody (species 2).

[0058] In an alternative embodiment, the epitope sequence to be inserted or engineered into the "background" protein or first polypeptide from a first species is First, the two amino acid sequences are aligned and differences up to one amino acid residue are highlighted. Selecting at least one (or more) of such amino acid residue differences; It is derived by modifying the backbone sequence (species 1) by changing one or more selected amino acids.

[0059] In an alternative embodiment, after one or more selected epitopes have been introduced into the backbone sequence, the derived hybrid (or chimeric) protein is recombinantly expressed and, if appropriate, purified for use in immunization of species 1, and the resulting polyclonal antibodies (or monoclonal antibodies derived from this humoral response) can be applied to recognize the protein in species 2.

[0060] In an alternative embodiment, a hybrid or chimeric protein is considered ready for immunization if it can be maintained in solution at a concentration of at least about 50 μg per mL for at least one day. Further quality control may be optionally performed prior to immunization to verify proper protein structure via immunological and / or biochemical testing, or by spectroscopic testing (e.g., circular dichroism).

[0061] In an alternative embodiment, when polyclonal antibodies are used for assays that involve intact proteins, such as ELISA, turbidimetric and CLIA assays, e.g. - Align two amino acid sequences and highlight differences up to one amino acid, - highlighting the differences on a 3D structure of the protein or domain; - Identify discrepancies that exist within the surface exposed areas; - selecting at least one of such surface exposure differences; and / or - modifying the backbone sequence (species 1) by changing selected amino acids to those of species 2; It may be advantageous to include further steps.

[0062] In some cases, the 3D structure of the protein or domain may be unknown and the second and third steps cannot be applied. Instead, in an alternative embodiment, a series of hybrid proteins with different epitope sequences are tested until the desired antibody is elicited.

[0063] Exemplary Applications for Making and Using the Chimeric Proteins Presented herein Prevention of Undesirable Antibody Reactivity or Characteristics In alternative embodiments, the recombinant polypeptides provided herein are used or the methods provided herein further comprise: - increasing the specificity for one homologous protein species in a family, for example by avoiding epitopes in the backbone sequence from the applied species 2 that are present in other members of the protein family (in species 2), so that the immune response is directed, i.e. more focused, on the remaining epitopes that are more unique for the selected protein species; - to increase the specificity for one domain among many in a protein [this can be done by removing epitopes present in other domains (species 2) of the protein family, so that the immune response is directed to the remaining epitopes that are more unique for the selected domain], - increasing the cooperativity of a polyclonal antibody composition for a given application (one example is obtaining reactivity against a subset of epitopes to cause rapid and efficient cross-linking in a turbidimetric reaction; another example is generating polyclonal antibodies that can cooperate with monoclonal antibodies in assays such as ELISA or CLIA (e.g., by removing epitopes recognized by monoclonal antibodies), - preventing undesirable characteristics of polyclonal antibodies, for example by selectively removing epitopes from the species 2 sequence, so that subtypes of paratopes on the antibody are avoided (for example key characteristics such as the isoelectric point (pI) and hydrophobicity of the antibody can be influenced or controlled to provide desirable characteristics when interacting with other substances (one example is the interaction with plastic surfaces)); - exerting greater control over the polyclonal antibody manufacturing process so that the polyclonal antibodies are more uniform from batch to batch (one example would be removing one or more immunodominant epitopes from the species 2 sequence until a consistent and highly reactive response to minor epitopes is achieved in immunized animals; another example would be eliminating or removing the weakest epitopes from the species 2 polypeptide to avoid a highly variable response to such elements); and / or - Reducing the reactivity (e.g. reaction rate) to a given protein by removing some epitopes and / or reducing the antibody affinity by using one or more modified epitopes (or inserting them into the species 2 sequence) (this is useful for applications such as a wide range of turbidimetric assays).

[0064] Adding desired reactivity or characteristics In alternative embodiments, the recombinant polypeptides provided herein are used or the methods provided herein further comprise: - multi-species reactivity, so that the same antibody can be used, for example, for diagnosis of both human and animal species (this antibody can be generated by inserting additional epitopes into the species 1 backbone or by combining or fusing different recombinant proteins with different epitopic characteristics or with different newly inserted epitopes), - multiprotein reactivity, such that all or a selected subset of a protein family are recognized by polyclonal antibodies (this can be achieved by adding or inserting epitopes into the species 1 backbone that differ among family members, or by combining hybrid proteins with different versions of selected epitopes in the immunization mixture); - multi-domain reactivity, such that all or a selected subset of the domain types are recognized by polyclonal antibodies (this can be achieved by adding epitopes to the species 1 backbone that differ between the domains, or by combining hybrid domains with different versions of selected epitopes in the immunization mixture); - reactivity against epitopes that do not give rise to a primary response (it is possible to overcome the lack of a primary response against a given epitope by using a series of modified epitopes, as shown, for example, by Escolano, et al., 2016, Cell 166, 1445-1458, for the development of a vaccine against a virus; this approach using sequential immunizations can also be used for the production of polyclonal antibodies), and / or -Enhancing the desired characteristics of polyclonal antibodies, for example by selectively removing epitopes from the species 2 sequence so that subtypes of paratopes on the antibody are avoided (key characteristics such as the pI and hydrophobicity of the antibody can be influenced or controlled to provide desirable characteristics when interacting with other substances, for example when interacting with plastic surfaces).

[0065] In an alternative embodiment, humoral immunity is an immune response that involves the transformation of B cells into plasma cells that produce and secrete antibodies against a specific antigen.

[0066] In an alternative embodiment, an epitope, also known as an antigenic determinant, is the part of an antigen that is recognized by an antibody.

[0067] In an alternative embodiment, the paratope, also called the antigen-binding site, is the part of an antibody that recognizes and binds to an antigen.

[0068] In an alternative embodiment, the isoelectric point (pI) is the pH of a solution where the net charge of a protein is 0. At a solution pH above the pI, the surface of a protein is predominantly negatively charged and therefore exhibits repulsive forces with similarly charged molecules.

[0069] Vaccines and vaccinations In alternative embodiments, vaccine formulations are provided that comprise the chimeric or recombinant polypeptides presented herein, nucleic acids encoding them, including DNA protein-coding molecules and RNA protein-coding molecules (e.g., protein-encoding mRNA), or nucleic acid expression vehicles, and / or cells presented herein.

[0070] In alternative embodiments, the vaccine formulations presented herein comprise or further comprise an adjuvant or incomplete adjuvant, or a pharma- ceutically acceptable excipient, where appropriate, the pharma-ceutically acceptable excipient comprises sterile buffer, saline, or water.

[0071] In alternative embodiments, the chimeric or recombinant polypeptides provided herein, the nucleic acids encoding them (e.g., protein-encoding RNA), or nucleic acid expression vehicles are formulated in liposomes, e.g., as liposome delivery vehicles (e.g., cationic liposomes) having a polycationic lipid composition and / or liposomes having a cholesterol backbone conjugated to polyethylene glycol, exemplary cationic liposome compositions include or are produced using N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA) and cholesterol, N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTAP) and cholesterol, 1-[2-(oleoyloxy)ethyl]-2-oleyl-3-(2-hydroxyethyl)-imidazolinium chloride (DOTIM) and cholesterol, dimethyldioctadecylammonium bromide (DDAB) and cholesterol, and combinations thereof.

[0072] For example, in alternative embodiments, the nucleic acid encoding the protein may be DNA encoding one or more immunogenic peptides or proteins, and the DNA may be carried in an expression vehicle such as a viral vector, for example an adenoviral vector such as Ad5, or an adeno-associated vector (AAV). In alternative embodiments, the recombinant adenovirus used in the vaccines presented herein may be as described in US Patent Application No. US20200399323(A1), which describes recombinant adenoviruses containing deletions in the E1 region or deletions in the E1 region or any deletion that renders the virus replication-deficient (e.g., the replication-deficient virus may contain deletions in one or more of the E1, E3, and / or E4 regions), or as described in US Patent Application No. US20190382793(A1), which describes methods for producing recombinant adenoviruses for gene therapy.

[0073] In alternative embodiments, the nucleic acid encoding the protein may be RNA, e.g., mRNA, which may be formulated in a lipid formulation or liposome and injected, e.g., intramuscularly (IM), e.g., using the formulations and methods described in U.S. Patent Application No. US20210046173(A1), which describes delivering to a subject (e.g., via intramuscular administration) an immunogenic composition comprising an RNA (e.g., mRNA) that comprises an open reading frame (ORF) that comprises (or consists of, or consists essentially of) an immunogenic or antigenic sequence as presented herein, and optionally the RNA (or DNA-loaded expression vehicle) is coupled to a non-cationic lipid, including a mixture of cholesterol and DSPC, or PEG lipid, or PEG-modified lipid, or LNP, or ionizable cationic lipid, or (13Z,16Z)-N,N-dimethyl-2-nonylhenicos-12,15-dien-1-amine, cholesterol, DSPC, and PEG-2000. The PEG lipid is formulated in liposomes, or lipid nanoparticles (LNPs), or nanoliposomes, containing a mixture of DMG.In alternative embodiments, the PEG lipid is 1,2-dimyristoyl-sn-glycerol methoxypolyethylene glycol (PEG-DMG), PEG-disterylglycerol (PEG-DSG), PEG-dipalmetoleyl, PEG-dioleyl, PEG-distearyl, PEG-diacylglycamide (PEG-DAG), PEG-dipalmitoylphosphatidylethanolamine (PEG-DPPE), or PEG-1,2-dimyristyloxylpropyl-3-amine (PEG-c-DMA), or the PEG lipid is PEG coupled to dimyristoylglycerol (PEG-DMG).

[0074] In alternative embodiments, the chimeric or recombinant polypeptides presented herein, the nucleic acids encoding them, or the nucleic acid expression vehicles are formulated or administered with an adjuvant, such as aluminum hydroxide or mineral oil, immune response stimulants such as lipid A, proteins from Bordetella pertussis or Mycobacterium tuberculosis; such as Freund's incomplete and complete adjuvants (Difco Laboratories, Detroit, Mich.); Merck Adjuvant 65 (Merck and Company, Rahway, NJ); AS-2 (GlaxoSmithKline, Philadelphia, Pa.); aluminum salts such as aluminum hydroxide gel (alum) or aluminum phosphate; salts of calcium, iron, or zinc; insoluble suspensions of acylated tyrosine; acylated saccharides; cationic or anionic derivatized polysaccharides; polyphosphazenes; biodegradable microspheres; monophosphoryl lipid A and quil A. Cytokines such as GM-CSF, interleukin-2, interleukin-7, interleukin-12, and other similar growth factors may also be used as adjuvants.

[0075] In alternative embodiments, the chimeric or recombinant polypeptides presented herein, the nucleic acids encoding them, or the nucleic acid expression vehicles are administered in one or more dosing regimens.

[0076] In alternative embodiments, the chimeric or recombinant polypeptides provided herein, the nucleic acids encoding them, or the nucleic acid expression vehicles, or the vaccines provided herein are administered at a dose of between about 100 μg and about 1 mg, or between about 50 μg and 500 μg, or between about 1 mg and about 10 mg. The vaccine may be administered, for example, in a single dose, or in two, three, four, or five or more doses. In one embodiment, two doses are administered at an interval of one or two weeks.

[0077] In alternative embodiments, the chimeric or recombinant polypeptides presented herein, the nucleic acids encoding them, or the nucleic acid expression vehicles, or the vaccines presented herein are administered via an intradermal, transdermal, intranasal route (e.g., by nasal drops or intranasal aerosol delivery), intramuscular, subcutaneous, or sublingual route.

[0078] In alternative embodiments, the chimeric or recombinant polypeptides presented herein, the nucleic acids encoding them, or the nucleic acid expression vehicles, or the vaccines presented herein, are administered using a syringe, a pneumatic injector, or a jet injection device.

[0079] Products and Kits Articles of manufacture and kits for practicing the methods presented herein are provided, including, for example, nucleic acids such as expression vehicles for expressing a chimeric or recombinant polypeptide presented herein, or a chimeric polypeptide presented herein, or a cell expressing a chimeric or recombinant polypeptide presented herein, or a vaccine formulation presented herein, including, for example, a chimeric or recombinant polypeptide presented herein, and optionally, the articles of manufacture and kits can further include instructions for practicing the methods presented herein.

[0080] Any of the above aspects and embodiments may be combined with any other aspect or embodiment disclosed herein in the Summary, Drawings, and / or Detailed Description sections.

[0081] As used in this specification and claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

[0082] Unless otherwise specified or apparent from the context, the term "or" as used herein is understood to be inclusive and includes both "or" and "and."

[0083] Unless otherwise specified or obvious from the context, the term "about" as used herein is understood to mean within the normal tolerance in the art, for example, within 2 standard deviations of the mean. About can be understood to mean within 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the specified value. Unless otherwise clear from the context, all numerical values ​​presented herein are modified with the term "about".

[0084] Unless otherwise specified or apparent from the context, the terms "substantially all," "substantially most of," "substantially all of," or "the majority" as used herein include at least about 90%, 95%, 97%, 98%, 99%, or 99.5% or more of the referenced amount of the composition.

[0085] Each patent, patent application, publication, and document referred to herein is hereby incorporated by reference. Citation of such patents, patent applications, publications, and documents is not an admission that any of the foregoing is pertinent prior art, nor does it constitute an admission as to the contents or dates of such publications or documents. The incorporation by reference of any such document alone shall not be construed as a representation or admission that any part of the contents of any document is believed to be essential material to satisfy the disclosure requirements of any country or region law for patent applications. The right to rely on any such document, if necessary, to provide material deemed essential to the subject matter of a patent claim by an examining authority or court is reserved.

[0086] Modifications may be made to the foregoing without departing from the basic aspects of the invention. Although the present invention has been described in sufficient detail with reference to one or more specific embodiments, those skilled in the art will recognize that modifications may be made to the embodiments specifically disclosed in this application and that these modifications and improvements will still fall within the scope and spirit of the invention. The present invention illustratively described herein may be suitably practiced in the absence of any element not specifically disclosed herein. Thus, for example, in each instance herein, the terms "comprising," "consisting essentially of," and "consisting of" may all be replaced with either of the other two terms. Thus, the terms and expressions used are used as descriptive terms rather than limiting terms, and equivalents of the features shown and described or portions thereof are not excluded, recognizing that various modifications are possible within the scope of the invention. The embodiments of the present invention are described in the following claims.

[0087] The present invention will be further described with reference to the embodiments described herein, but it will be understood that the invention is not limited to such embodiments. EXAMPLES

[0088] Unless otherwise specified in the examples, all recombinant DNA techniques are performed according to standard protocols as described, for example, in Sambrook et al. (2012) Molecular Cloning: A Laboratory Manual, 4th Edition, Cold Spring Harbor Laboratory Press, NY, and Ausubel et al. (1994) Current Protocols in Molecular Biology, Current Protocols, USA, volumes 1 and 2. Other references for standard molecular biology techniques include Sambrook and Russell (2001) Molecular Cloning: A Laboratory Manual, Third Edition, Cold Spring Harbor Laboratory Press, NY, and Brown (1998) Molecular Biology LabFax, Second Edition, Academic Press (UK), volumes I and II. Standard references and methods for the polymerase chain reaction can be found in Dieffenbach and Dveksler (1995) PCR Primer: A Laboratory Manual, Cold Spring Harbor Laboratory Press, and McPherson at al. (2000) PCR - Basics: From Background to Bench, First Edition, Springer Verlag, Germany.

[0089] [Example 1] Production and Use of Chimeric Immunogens This example describes an exemplary method for making and using the chimeric immunogens presented herein.

[0090] material and method Epitope Selection Human epitopes were identified based on sequence alignment and epitope mapping performed using the existing DAKO / Agilent polyclonal antibody A0101 and the constant domain of the human free light chain. The identified epitopes were used to design chimeric variants reactive against species 2 but not species 1.

[0091] Protein expression and purification All constructs encoding chimeric variants of λ-FLC were ordered through GENSCRIPT® or cloned into pET22(+). Constructs were designed with an N-terminal His tag followed by a TEV cleavage site to separate the His tag from the λ-FLC constant domain. E. coli strain BL21 (Invitrogen™) was used to express recombinant rabbit λ-FLC constant domain and chimeric constant domain variants with human epitopes grafted onto a rabbit scaffold in the periplasm. Lysogeny broth medium containing recombinant proteins was dialyzed against binding buffer (20 mM Na2HPO4, 150 mM NaCl, pH 7.4) before the recombinant proteins were immobilized by affinity chromatography (IMAC) using a His tag column (GE Healthcare). The immobilized protein was washed with at least 15 column volumes of wash buffer (20 mM Na2HPO4, 1 M NaCl, 20 mM imidazole, pH 7.4) and eluted with elution buffer (20 mM Na2HPO4, 150 mM NaCl, 500 mM imidazole, pH 7.4). The His-tagged recombinant protein was dialyzed into cleavage buffer (20 mM Tris, 150 mM NaCl, pH 8) followed by the addition of TEV protease (0.2 mg / mL, final concentration) supplemented with 2 mM reduced L-glutathione (final concentration). The cleavage reaction was left overnight at +4 °C. To separate the cleaved recombinant protein from the His-tag, TEV protease, and uncleaved recombinant protein, the mixture was loaded onto the His-tag column and the flow-through containing the untagged recombinant protein was collected. The samples were further purified using size exclusion chromatography (SEC) SUPERDEX 75™ Prep Grad (GE Healthcare) with binding buffer as eluent. Analyses (ELISA and turbidimetric assays) showed that the recombinant protein retained the His8 tag.

[0092] SDS-PAGE and Western blotting Protein purity was followed by SDS-PAGE using precast NUPAGE™ 4-12% Bis-Tris gels (Invitrogen™). All protein samples were loaded with SDS sample buffer (350 mM Tris.HCL, 357 mM sodium dodecyl sulfate, 44.6% glycerol, 179 μM bromophenol blue, pH 6.8) and run in MES SDS running buffer (NOVEX™). Gels were stained with SimplyBlue™ (Invitrogen™). For Western blotting, proteins were separated using NUPAGE™ 4-12% Bis-Tris gels (Invitrogen™) and MES SDS running buffer (NOVEX™). Electroblotting was performed for 1 h at 30 V and proteins were transferred to a PVDF membrane (BioRad) in Western Blot buffer (25 mM Tris, 0.192 M glycine and 25.3% ethanol). Blotting was followed by a blocking step using blocking buffer (50 mM Tris-HCL, 0.5 M NaCl, 0.5% Tween20, pH 9.0). The blocked PVDF membrane containing the transferred proteins was incubated overnight with primary pAb (rabbit anti-E. coli diluted 1:1000) for 1 h (minimum) at +4° C. with shaking. The membrane was washed 4×10 min with blocking buffer before incubating it with secondary pAb (swine anti-rabbit) for 1 h. After incubation with secondary pAb, the membrane was washed 4×10 min with blocking buffer and incubated with DAB (diaminobenzidine) and substrate for 20 min.

[0093] Antigen preparation and immunization Based on SDS-PAGE and Western blotting analysis of fractions from SEC purification, highly pure antigen samples were generated. Only impurity-free fractions were included in the final antigen sample. This antigen sample constitutes equal amounts of three constant domain variants of chimeric lambda-FLC (LAC1, LAC2+3, LAC7) to elicit pAb ensembles containing paratopes of the four isoforms of human free light chain. Three-month-old rabbits were immunized subcutaneously immediately after mixing the antigen sample with equal amounts (1:1) of Freund's incomplete adjuvant (FIA). Serum was collected before immunization and 7 weeks after the last immunization. Serum was preserved by adding sodium azide (NaN3) to a final concentration of 15 mM and stored at 4 °C.

[0094] Enzyme-linked immunosorbent assay (ELISA) All antigens (λ-FLC-, rabbit λ-FLC constant domain, chimeric variants of human λ-FLC or human intact IgG) were diluted to 1 μg / mL in coating buffer (10 mM Na2HPO4, 145 mM NaCl, 0.1% Tween-20, pH 7.2) and used to coat 96-well plates overnight at 4° C. All primary pAbs (A0101, X0903, and the IgG fraction from Example 1 (IgG example1 )) was diluted in 5% skim milk in a 3-fold series starting at 10 μg / mL. The plates were washed using wash buffer (10 mM Na2HPO4, 500 mM NaCl, 0.1% Tween-20, pH 7.2) and incubated with the primary pAb for 1 h at room temperature with agitation. Then, they were washed with wash buffer and incubated with the secondary pAb (P0448) diluted to 10 μg / mL in 5% skim milk for 1 h with agitation. Finally, the plates were washed with wash buffer and developed for 5 min after adding 100 μL per well of TMB (DAKO S1599). The reaction was stopped by adding 100 μL of 0.5 M H2SO4 to each reaction well. The results were detected by an ELISA reader using SOFTMAX™ 6.2.1 at detection wavelengths of 450 nm and 650 nm.

[0095] 1A-C show the transfer of human epitopes to the rabbit scaffold.

[0096] FIG. 1A shows a sequence alignment of human (SEQ ID NO:2) and rabbit (SEQ ID NO:1) λ-FLC constant domain sequences, where sequence differences were found using sequence alignment.

[0097] FIG. 1B shows a schematic representation of selected epitopes that include species-specific sequences located within the selected cryptic regions.

[0098] FIG. 1C shows the chimeric sequences of rhLAC1 (SEQ ID NO: 3), rhLAC2+3 (SEQ ID NO: 4), and rhLAC7 (SEQ ID NO: 5), in which selected epitopes (black, underlined and bold) have been grafted into rabbit backbone sequences (teal), which were synthesized and inserted into expression vectors.

[0099] [Example 2] This example describes exemplary methods for making and using the recombinant or chimeric immunogens presented herein.

[0100] This example is similar to Example 1, but Example 1 provides a proof of concept, and Example 2 uses this concept to develop a specific pAb against λ-FLC. This is achieved by refining the selected epitope.

[0101] material and method Epitope Selection Rabbit and human lambda free light chain (λ-FLC) sequences were fetched from the database (PIR:A30505 and P0DOX8, respectively). The sequences were aligned to identify sequence differences in the λ-FLC constant domain between the two species. Epitope selection was performed by aligning and inspecting the crystal structures of human λ-FLC (PDB entry:1a8j) and intact human IgG (PDB entry:1hzh). Using the PISA server, surface epitopes with less than 10% solvent exposed residues were identified. These residues were included in chimeric variants to generate specific λ-FLC pAbs. See Figure 14.

[0102] Protein expression and purification See Example 1 section.

[0103] SDS-PAGE and Western blotting See Example 1 section.

[0104] Antigen preparation and immunization Based on SDS-PAGE and Western blotting analysis of fractions from SEC purification, highly pure antigen samples were generated. Only impurity-free fractions were included in the final antigen sample. This antigen sample constitutes a single chimeric λ-FLC constant domain variant with all human epitopes to induce a pAb ensemble with the ability to interact equally well with all isotypes of human free light chains. Three-month-old rabbits were immunized subcutaneously immediately after mixing the antigen sample with Freund's incomplete adjuvant (FIA) in equal volumes (1:1). Serum was collected before immunization and 7 weeks after the last immunization. Serum was preserved by adding sodium azide (NaN3) to a final concentration of 15 mM and stored at 4 °C.

[0105] Enzyme-linked immunosorbent assay (ELISA) Human intact IgG and SEC-purified IgG were diluted to 1 μg / mL in coating buffer (10 mM Na2HPO4, 145 mM NaCl, 0.1% Tween-20, pH 7.2) and used to coat 96-well plates overnight at 4° C. All primary pAbs (A0101, IgG fraction from Example 1 (IgGf exampel1 ), and the IgG fraction of Example 2 (IgGf exampel2 )) was diluted in 5% skim milk in a 3-fold series starting from 10 μg / mL. The plate was washed using wash buffer (10 mM Na2HPO4, 500 mM NaCl, 0.1% Tween-20, pH 7.2) and incubated with the primary pAb for 1 h at room temperature with agitation. Then, it was washed with wash buffer and incubated with the secondary pAb (anti-rabbit IgG, P0448) diluted to 10 μg / mL in 5% skim milk for 1 h with agitation. Finally, the plate was washed with wash buffer and developed for 5 min after adding 100 μL per well of TMB (DAKO S1599). The reaction was stopped by adding 100 μL of 0.5 M H2SO4 to each reaction well. The results were detected by an ELISA reader using SOFTMAX™ 6.2.1 at detection wavelengths of 450 nm and 650 nm.

[0106] Aggregation assay Turbidimetric assays were performed using an ABX Pentra400 (HORIBA) instrument to measure the increase in agglutination over time. To examine the aggregates formed during the agglutination reaction, the wavelengths of the instrument were adjusted to 340 nm and 700 nm. The analysis cup contained 154 μl of S2007 buffer (DAKO), 8 μL of antigen, 31 μL of pAb, and 5 μL of H2O for a final reaction volume of 198 μL. Antigen was diluted to 2 mg / mL (human IgG, 0.54 μM final concentration) or 1 mg / mL (rabbit IgG, 0.27 μM final concentration), from which each dilution step was diluted twice to give nine final concentrations. All agglutination experiments were performed at a pAb concentration of 10 mg / mL (10.5 μM final concentration) to ensure that the low density IgG subpopulation was also within the measurable range.

[0107] [Example 3] This example describes an exemplary method for making and using the chimeric or recombinant immunogens presented herein.

[0108] In this example, the number of potential epitopes in the antigen (or immunogen) was reduced, e.g., several hydrophobic epitopes were removed, with the intent of developing polyclonal antibodies with paratopes of reduced hydrophobicity. These changes would increase the utility of polyclonal antibodies in particle-enhanced turbidimetry.

[0109] material and method Epitope Selection Human and rabbit serum amyloid A1 (SAA1) sequences were fetched from the database (Uniprot: P0DJI8 and P53614, respectively). The sequences were aligned to identify sequence differences in hydrophobic regions between the two species. Epitope selection was performed by aligning and inspecting the crystal structure of human SAA1 (PDB entry: 4IP8). Residues involved in hydrogen bonds were not selected.

[0110] Protein expression and purification Constructs encoding chimeric variants of SAA1 or rabbit SAA were ordered from GENSCRIPT® as plasmids cloned into pET30a(+). Constructs were designed with an N-terminal His tag followed by a TEV cleavage site to separate the His tag from the SAA1 domain. E. coli strain BL21 (Invitrogen™) was used to express recombinant rabbit SAA1 domain and chimeric SAA1 domain variants with human epitopes grafted onto a rabbit scaffold in inclusion bodies. Cells were harvested, resuspended in 8M urea, 20mM Tris, pH 8.5, spun, and filtered through a 0.2μm filter before the recombinant proteins were immobilized by affinity chromatography (IMAC) using a His tag column (GE Healthcare). The immobilized protein was washed with at least 15 column volumes of wash buffer (20 mM Tris-HCL, 1 M NaCl, 20 mM imidazole, pH 8.5) and eluted with elution buffer (20 mM Tris-HCL, 150 mM NaCl, 500 mM imidazole, pH 8.5). The His-tagged recombinant protein was dialyzed against 20 mM Tris-HCl pH 8.5 buffer, followed by the addition of TEV protease (0.2 mg / mL, final concentration) supplemented with 2 mM dithiothreitol (DTT, final concentration). The cleavage reaction was left for a minimum of 4 h, after which the cleaved recombinant protein was separated from the His-tag, TEV protease, and uncleaved recombinant protein by loading the mixture onto a His-tag column. The flow-through containing the untagged recombinant protein was collected. The sample was unfolded by dialysis against binding buffer and further purified using size exclusion chromatography (SEC) SUPERDEX 75 PREP GRAD™ (GE Healthcare) with binding buffer as eluent. Finally, the SEC-purified recombinant protein was refolded by dialysis against 20 mM Tris, pH, and used as antigen. In the analysis (ELISA and agglutination assay), the recombinant protein was able to retain the His8 tag.

[0111] SDS-PAGE and Western blotting Protein purity was followed by SDS-PAGE using precast NuPage 4-12% Bis-Tris gels (Invitrogen™). All protein samples were loaded with SDS sample buffer (350 mM Tris.HCL, 357 mM sodium dodecyl sulfate, 44.6% glycerol, 179 μM bromophenol blue, pH 6.8) and run in MES SDS running buffer (NOVEX™). Gels were stained with SimplyBlue™ (Invitrogen™). For Western blotting, proteins were separated using NuPage 4-12% Bis-Tris gels (Invitrogen™) and MES SDS running buffer (Novex™). Electroblotting was performed for 1 h at 30 V and proteins were transferred to a PVDF membrane (BioRad) in Western blot buffer (25 mM Tris, 0.192 M glycine and 25.3% ethanol). Blotting was followed by a blocking step using blocking buffer (50 mM Tris-HCL, 0.5 M NaCl, 0.5% Tween 20, pH 9.0). The blocked PVDF membrane containing the transferred proteins was incubated overnight with shaking at +4°C with primary pAb (rabbit anti-E. coli diluted 1:1000) for 1 h (minimum). The membrane was washed 4x10 min with blocking buffer before incubating with secondary pAb (swine anti-rabbit) for 1 h. After incubation with secondary pAb, the membrane was washed 4x10 min with blocking buffer and incubated with DAB (diaminobenzidine) and substrate for 20 min.

[0112] Antigen preparation and immunization Based on SDS-PAGE and Western blotting analysis of fractions from SEC purification, highly pure antigen samples were generated. Only impurity-free fractions were included in the final antigen sample. Antigen samples were mixed with Freund's incomplete adjuvant (FIA) in equal volumes (1:1) immediately prior to subcutaneous immunization of 3-month-old rabbits. Serum was collected before immunization and 7 weeks after the last immunization. Serum was preserved by adding sodium azide (NaN3) to a final concentration of 15 mM and stored at 4°C.

[0113] Transfer of human epitopes onto rabbit scaffolds: Sequence alignment was used to find sequence differences between human and rabbit serum amyloid A (SAA) as shown in Figure 18A, with the human sequence as SEQ ID NO: 9 and the rabbit sequence as SEQ ID NO: 10. Figure 18B shows the chimeric serum amyloid A (SAA) sequence (SEQ ID NO: 11) and indicates selected epitopes (black, underlined and bold) that contain species-specific sequences located within hydrophilic regions that have been grafted into the rabbit backbone (red) sequence.

[0114] FIG. 19 shows schematic images of SAA, the image on the left showing the human epitopes (lighter shading, or yellow residues) grafted onto the rabbit backbone (red) sequence.

[0115] The synthesized sequences were inserted into an expression vector, and the chimeric proteins were expressed in E. coli and purified prior to immunization.

[0116] [Example 4] This example describes an exemplary method for making and using the chimeric or recombinant immunogens presented herein.

[0117] In this example, constructs were designed to allow immunized rabbits to generate polyclonal antibodies against a cryptic epitope within the human kappa light chain constant domain. Such antibodies are expected to be specific for human kappa free light chains and therefore may be used, for example, for diagnostic purposes in samples from myeloma patients.

[0118] material and method Epitope Selection Human and rabbit kappa free light chain (κ-FLC) sequences were fetched from the database (Uniprot: P01834 and P01840, respectively). The sequences were aligned to identify sequence differences in the κ-FLC constant domain between the two species. Epitope selection was performed by aligning and inspecting the crystal structures of human κ-FLC (PDB entry: 6n35) and intact human IgG (PDB entry: 1hzh). Surface epitopes with less than 10% solvent exposed residues were identified using the PISA server. These residues were included in chimeric variants to generate specific κ-FLC pAbs.

[0119] Protein expression and purification Constructs encoding chimeric variants of κ-FLC or rabbit κ-FLC(B4) were ordered from GENSCRIPT® as plasmids cloned into pET22(+). Constructs were designed with an N-terminal His tag followed by a TEV cleavage site to separate the His tag from the κ-FLC constant domain. E. coli strain BL21 (Invitrogen™) was used to express recombinant rabbit κ-FLC constant domain and chimeric constant domain variants with human epitopes grafted onto a rabbit scaffold in the periplasm. Lysogeny broth medium containing recombinant proteins was dialyzed against binding buffer (20 mM Na2HPO4, 150 mM NaCl, pH 7.4) before the recombinant proteins were immobilized by affinity chromatography (IMAC) using a His tag column (GE Healthcare). The immobilized protein was washed with at least 15 column volumes of wash buffer (20 mM Na2HPO4, 1 M NaCl, 20 mM imidazole, pH 7.4) and eluted with elution buffer (20 mM Na2HPO4, 150 mM NaCl, 500 mM imidazole, pH 7.4). The His-tagged recombinant protein was dialyzed against binding buffer, followed by the addition of TEV protease (0.2 mg / mL, final concentration) supplemented with 2 mM reduced L-glutathione (final concentration). After leaving the cleavage reaction for 4 hours, the cleaved recombinant protein was separated from the His-tag, TEV protease, and uncleaved recombinant protein, the mixture was loaded onto the His-tag column, and the flow-through containing the untagged recombinant protein was collected. The sample was further purified using size-exclusion chromatography (SEC) SUPERDEX 75 PREP GRAD™ (GE Healthcare) with binding buffer as eluent. Analyses (ELISA and agglutination assays) showed that the recombinant protein was able to retain the His8 tag.

[0120] SDS-PAGE and Western blotting As described in Example 1.

[0121] Antigen preparation and immunization Based on SDS-PAGE and Western blotting analysis of fractions from SEC purification, highly pure antigen samples were generated. Only impurity-free fractions were included in the final antigen sample. Antigen samples were mixed with Freund's incomplete adjuvant (FIA) in equal volumes (1:1) immediately prior to subcutaneous immunization of rabbits. Serum was preserved by adding sodium azide (NaN3) to a final concentration of 15 mM and stored at 4°C.

[0122] Transfer of human epitopes onto rabbit scaffolds FIG. 20A shows how sequence alignment was used to discover sequence differences between human (SEQ ID NO: 12) and rabbit (SEQ ID NO: 13) κ-FLC constant domains.

[0123] FIG. 20B shows a chimeric sequence (SEQ ID NO: 14) in which selected epitopes (black, underlined and bold) were grafted into the rabbit backbone (blue) sequence.

[0124] FIG. 21 shows the selected epitopes (lighter shading, or yellow, in the image on the left), which were species-specific sequences located within the selected cryptic regions.

[0125] The chimeric sequence was synthesized and inserted into an expression vector.

[0126] Antigen preparation The expression constructs were transformed into cells from the appropriate organism and used for the production of recombinant proteins. The proteins were purified using standard methods such as HIS capture columns and size exclusion columns (SEC).

[0127] FIG. 22A shows an SDS-PAGE showing protein expression to demonstrate overexpression of the protein in both the pellet (P) and supernatant (S) with the expected band of approximately 13-14 kDa (arrow).

[0128] FIG. 22B shows an SDS-PAGE demonstrating protein purity after TEV cleavage and SEC.

[0129] FIG. 22C shows a Western blot (WB) showing protein purity after TEV cleavage and SEC.

[0130] Based on SDS-PAGE and WB, pure fractions (F x ) were pooled to constitute the antigen. In Western blot DAKO A0100, polyclonal κ-FLC products were used as positive controls (10) to demonstrate functionality of the chimeric antigens. The functionality of the anti-E. coli pAb used to check sample purity has been shown previously (λ-FLC example, see Figure 2C).

[0131] For size determination by SDS-PAGE, BENCHMARK™ Molecular weights (220, 160, 120, 100, 90, 80, 70, 60, 50 40, 30, 25, 20, 15, 10 kDa) were used, and for WB PAGERULER™, a prestained protein ladder (180, 130, 100, 70 (orange), 55, 40, 35, 25, 15, 10 (green) kDa) was used.

[0132] Figure 23 shows ELISA data showing that antisera from rabbits immunized with chimeric rhKappa-Cd are specific and show little or no reactivity to recombinant rabbit kappa constant domain (D) but reactivity to human Kappa-FLC (B). The antisera also show lower reactivity to intact human IgG (A), indicating that it is more specific than the control A0100.

[0133] FIG. 24 shows agglutination experiments showing that the antiserum can agglutinate human κ-FLC(C) but not intact human IgG, demonstrating that the antiserum reacts with more than one epitope and that these epitopes are hidden in intact human IgG.

[0134] [Example 5] Preparation of chimeric antigens This example describes an exemplary method for making and using the chimeric immunogens presented herein.

[0135] For human IgG subtypes 1-4, we designed antigens according to the methods presented herein, recombinantly produced the antigens, and purified them using chromatography.

[0136] material and method Epitope Selection Human IgG isotypes (1, 2, 3 and 4) and rabbit IgG sequences were aligned to identify isotypic sequence differences in the Ch1-Ch2-Ch3 region of IgG. Epitopes were carefully selected by inspecting the crystal structure of the entire IgG (pdb entry: 1hzh).

[0137] Protein expression and purification Standard HEK cell expression was followed by Protein A or Protein G purification and further purified by SEC using PBS as eluent.

[0138] SDS-PAGE and Western blotting As described in Example 1.

[0139] Antigen preparation and immunization Based on SDS-PAGE and Western blotting analysis of fractions from SEC purification, highly pure antigen samples were generated. Only impurity-free fractions were included in the final antigen sample. Antigen samples were mixed with Freund's incomplete adjuvant (FIA) in equal volumes (1:1) immediately prior to subcutaneous immunization of 3-month-old rabbits. Serum was collected before immunization and 7 weeks after the last immunization. Serum was preserved by adding sodium azide (NaN3) to a final concentration of 15 mM and stored at 4°C.

[0140] Transfer of human epitopes onto rabbit scaffolds: Figures 24A-B show how sequence alignment was used to discover sequence differences between human and rabbit gamma immunoglobulins (IgG). Chimeric sequences containing selected epitopes (Figure 24A: colored and underlined; Figure 25B, bold and underlined) were grafted into rabbit backbone sequences, synthesized, and inserted into expression vectors; rabbit backbone (SEQ ID NO: 15); rhIgG1 (SEQ ID NO: 16); rhIgG2 (SEQ ID NO: 17); rhIgG2_2 (SEQ ID NO: 18); rhIgG3 (SEQ ID NO: 19); rhIgG4 (SEQ ID NO: 20).

[0141] Figures 25A-F show rabbit IgG and chimeric IgG made by the methods presented herein in which human isotype-specific epitopes (colored) have been grafted onto a rabbit IgG backbone (gray). Figure 25A shows a rabbit IgG backbone with no human epitopes inserted, Figure 25B shows a chimeric IgG1 subtype with an inserted human epitope (colored), Figure 25C shows a chimeric IgG2 subtype with an inserted human epitope (colored), Figure 25D shows a chimeric IgG2_2 subtype with an inserted human epitope (colored), Figure 25E shows a chimeric IgG3 subtype with an inserted human epitope (colored), and Figure 25F shows a chimeric IgG4 subtype with an inserted human epitope (colored).

[0142] [Example 6] Preparation of recombinant human epitopes This example demonstrates that the substitution of a human epitope onto a non-human polypeptide background, in this example an immunoglobulin background, and in particular in this example a rabbit IgG background, can confer isotype specificity, or human IgG1, IgG2, IgG3 or IgG4 subtype specificity, of the antibody response by immunized animals (in this example, in immunized rabbits). In other words, when a human IgG1 epitope was generated in a rabbit immunoglobulin polypeptide (Ig) by substituting, for example, rabbit amino acids with amino acids of human IgG1, the antibody response by animals immunized with this chimeric Ig was specific for human IgG1 isotype Ig. The substituted human epitope replaced the rabbit epitope. In other words, the human epitope replaced the selected rabbit epitope.

[0143] Rabbit IgGs were constructed that carry (or have been substituted into) epitopes specific for human IgG1, IgG2, IgG3, and IgG4, as shown in Figure 27 A. The human epitopes (human amino acid residues substituted in the rabbit Ig) are shown in dark color.

[0144] As a graph, Figures 27B-E show rabbit immune responses to human IgG1, IgG2, IgG3, and IgG4 epitopes in rabbit Ig, respectively. In all four cases (human IgG1, IgG2, IgG3, and IgG4 epitopes), similarly low levels of background (dots) were observed. In contrast, rabbits immunized with rabbit IgG bearing epitopes specific for human IgG3 or IgG4 had high specific signals (solid titration curves), while rabbits immunized with rabbit IgG bearing epitopes specific for human IgG1 or IgG2 had lower (or moderate) specific signals.

[0145] Taken together, these data demonstrate that human epitopes, including but not limited to human Ig isotype epitopes, can be substituted onto a rabbit IgG background to result in a human epitope-specific immune response from rabbits (e.g., eliciting an IgG1-4 subtype response specificity in immunized rabbits).

[0146] Because rabbits immunized with rabbit IgG bearing epitopes specific for human IgG1 or IgG2 had lower (or moderate) specific signals, the two IgG1 or IgG2 subtypes were redesigned to improve rabbit reactivity to the Ig1 and IgG2 epitopes. The amino acid sequences of the modified variants of the chimeric IgG1 and IgG2 subtype immunogens are shown in Figure 27F, with the underlined amino acid residues representing the human epitopes.

[0147] [Example 7] Removal of selected epitopes This example shows how removal of specific epitopes (or replacement of one type of epitope with another) can result in improved performance of the resulting antibody. Specifically, it was shown that removal of selected human hydrophobic residues (substitution with non-hydrophobic residues) resulted in antibodies with reduced hydrophobicity and therefore reduced self-binding properties, and that reduced self-binding resulted in improved performance when the hydrophobic Igs were bound to beads in an agglutination reaction. In this example, the substituted epitopes were inserted into a rabbit serum amyloid A (SAA) polypeptide background or backbone.

[0148] FIG. 28A shows the rabbit serum amyloid A (SAA) backbone, with the red residues (or darker colors) being the rabbit SAA sequence and the yellow (or lighter colors) representing the inserted human-specific amino acids.

[0149] FIG. 28B shows human SAA with the residues colored blue (or darker) or circled indicating six hydrophobic residues that may interact with lipid surfaces.

[0150] As shown in Figure 28A, a chimeric SAA was constructed in which the six hydrophobic human (blue) sites, or circled residues, were replaced by the corresponding rabbit amino acids.

[0151] FIG. 28C shows antibodies derived from immunization with the SAA shown in FIG. 28A coupled to beads.

[0152] FIG. 28D shows that antibodies derived from immunization with SAA as shown in FIG. 28B result in immune particles with antibodies (Abs) that contain several paratopes that recognize human hydrophobic (blue) epitopes.

[0153] 28E-F show the kinetics of C and D in response to five different levels of SAA.

[0154] In Figures 28A-B, amino acid residues that differ in human SAA compared to rabbit SAA are shown in yellow (or lighter residues) and blue (or darker circled residues). In Figure 28B, the six blue (or darker circled) residues are hydrophobic epitopes that may be involved in binding of SAA to lipid particles.

[0155] When SAA polyclonal antibodies are conjugated to latex particles (Figure 28D), the surface contains a paratope specific for a hydrophobic epitope (indicated by blue or circled residues). When such beads are added to a reaction buffer containing SAA, an abnormal drop in OD is first observed. Then, as the beads bind to SAA and increase the turbidity of the fluid, the OD increases.

[0156] In contrast, when beads coupled to antibodies derived from immunization with SAA bearing rabbit sequences at the six blue, or circled, residue positions (as shown in Figure 28A) were used, the OD increased immediately, as usual.

[0157] A suggested explanation is that the six hydrophobic residues induce antibodies with some hydrophobic character in the paratopes. These hydrophobic paratopes may allow some binding of antibody-labeled beads. When such beads are placed in a reaction buffer, they disperse, causing a decrease in absorbance, until agglutination becomes dominant, causing an increase in absorbance.

[0158] The amino acid sequence of rabbit SAA with the inserted human amino acid residues is: [ka] where bolded residues indicate the non-hydrophobic inserted human residues and underlined residues indicate the rabbit hydrophobic residues.

[0159] [Example 8] Generation of slow-reactive epitopes This example shows the construction of a chimeric C-reactive protein (CRP) antigen substituted with only a few human-specific amino acid (aa) residues and demonstrates that immunization with this modified chimeric polypeptide can result in the generation of slow-reactive antibodies.

[0160] Figure 29 graphically displays data demonstrating that immunization with incomplete human epitopes can result in slow-reactive polyclonal antibodies (srpAb) against human CRP. Standard rabbit anti-human CRP polyclonal antibody is in blue and srpAb is in red. The srpAb was generated by immunizing rabbits with rabbit CRP carrying an artificial epitope that is part human and part rabbit. The srpAb was obtained from a fully immunized rabbit that received six immunizations over a three month period. The two antibodies were titrated to give the same concentration of antibody against human CRP.

[0161] Human epitopes can be found that induce the expression of slow-reactive anti-CRP antibodies. The upper or blue curve shows the absorption kinetics when using DAKO polyclonal rabbit anti-human CRP antibodies. The lower or red curve shows the absorption kinetics when using polyclonal rabbit anti-human CRP antibodies derived from immunization with rabbit CRP containing one human epitope. It will be understood that slow-reactive epitopes can also be generated by inserting at least one amino acid from a second species or deleting at least one amino acid from a first species.

[0162] [Example 9] Construction of polypeptide epitopes in the ferritin backbone. This example describes the construction of chimeric molecules comprising a rabbit ferritin backbone, or core, to which epitope-specific chimeric modules are attached via linkers.

[0163] In an alternative embodiment, recombinant ferritin forms self-assembling 24-mer homomers even if the protruding rods encoding the N- or C-termini are genetically altered to carry other protein sequences. The highly repeatable virus particle-like structure results in very high titers according to numerous published literature.

[0164] In an alternative embodiment, epitope-specific chimeric modules are attached to the rabbit ferritin backbone so that they protrude from a ferritin core, or ball, which can contain up to 24 recombinant ferritin molecules. Functionally, the rabbit ferritin is a "silent" carrier (meaning that no immune response is generated against the ferritin core in rabbits, since the ferritin originates from the species being immunized) to which multiple chimeric proteins are fused.

[0165] Figures 30A-B show an exemplary chimeric ferritin construct that includes a combined immunoglobulin antigen CDv6 from rabbit replaced with a human epitope (Figure 30A), with CDv6 shown separately in Figure 30B. The chimeric CDv6-ferritin antigen can generate or induce high levels of polyclonal antibodies to the human epitopes in CDv6, while the non-human sequences of the ferritin core or ball and CDv6 are non-immunogenic (i.e., do not generate an antibody response) in the species being immunized. Figure 30A shows an exemplary chimeric immunogen that includes a 24-mer rabbit ferritin fused to a chimeric rabbit CdV6 via a (GGGGS)5 linker (SEQ ID NO: 29), shown as a rod-like structure. Figure 30B shows a schematic of a chimeric CdV6 that includes a rabbit-human constant domain in gold (or lighter) and an inserted human epitope in red (or darker).

[0166] In an alternative embodiment, the linker connecting each of the individual ferritin molecules of the ferritin "ball" or core to the antigen motif is selected to be as non-immunogenic as possible and / or not present in proteins found in the human sample analyzed with the derived polyclonal antibody. For example, the linker can be a polyG-containing linker, such as a GGGGS (SEQ ID NO: 31) linker, or equivalent.

[0167] In an alternative embodiment, a "silent" or non-immunogenic ferritin carrier protein is made with one of two components, such as coiled-coil motifs, which can bind to each other to form a pair and bind to each other with high specificity. When the second component (or coiled-coil motif) binds to an immunogenic polypeptide such as CDv6, it "clicks" the CDv6 site onto the coiled-coil motif in individual recombinant ferritin molecules in (or on) the ferritin ball or core, so that the immunogenic polypeptide is displayed protruding from the ferritin ball or core. In this way, a ferritin ball or core with up to 24 copies of an immunogenic polypeptide such as CDv6 containing epitopes from different species can be made and used for immunization and high titer polyclonal antibodies specific to the immunogenic polypeptide, for example, specific to the human epitopes inserted into CDv6.

[0168] In an alternative embodiment, the coiled-coil motif comprises gamma-aminobutyric acid type B receptor subunit 1 isoform X1 (GBR1) and / or gamma-aminobutyric acid type B receptor subunit 2 (GBR2), wherein GBR1 can selectively bind to the GBR2 motif. Contains STNNNEEEKSRLLEKENRELEKIIAEKEERVSELRHQLQSR (sequence number 33).

[0169] In an alternative embodiment, the GBR2 motif is SVNQASTSRLEGLQSENHRLRMKITELDKDLEEVTMQLQDT (SEQ ID NO: 34).

[0170] In an alternative embodiment, the GBR1 motif is attached to the amino terminus of the ferritin molecule by use of a non-immunogenic linker, for example as shown below, where the GBR1 motif is underlined, the linker is in bold, and the remaining amino acid residues make up the ferritin molecule: [ka]

[0171] In an alternative embodiment, the chimeric antigen is linked to the amino terminus of a coiled-coil motif, such as a GBR1 or GBR2 motif, optionally covalently linked by a non-immunogenic linker.

[0172] In an alternative embodiment, a coiled-coil motif (optionally a GBR1 or GBR2 motif) bound or linked to a chimeric antigen (optionally CDv6) is bound (or is bound) to a coiled-coil motif (optionally a GBR1 or GBR2 motif) that is covalently bound or linked (optionally by using a non-immunogenic linker) to a ferritin molecule to generate a heterodimer as shown in Figure 34B.

[0173] In an alternative embodiment, no or minimal further purification is required since the coiled-coil rabbit ferritin ball and the CDv6 backbone are rabbit derived and therefore immunologically silent in rabbits.

[0174] In an alternative embodiment, the immunologically silent ferritin carrier protein is modified to have a sequence that allows for site-specific chemical modification. As an example, His(6)-Lys-His(3) (SEQ ID NO: 32) tags, known to confer acetylation hotspots, are inserted, and one His(6)-Lys-His(3) (SEQ ID NO: 32) tag per linker is attached to the linker distal to the ferritin core. By coupling recombinant ferritin-His(6)-Lys-His(3) (SEQ ID NO: 32) to the activation site, a ferritin ball containing up to 24 units of such protruding immunogenic sites is formed and applied for immunization.

[0175] Figure 31 shows an image of a Western blot showing that the pAb (sample 1108) used as the primary IgG raised against the immunogen CdV6, a chimeric rabbit human free light chain domain, interacts with the "B9" fraction from the size-exclusion purification column (columns #2 and #1 are different purification fractions) and with the "20 fraction" from size-exclusion. Note that the anti-human serum has no or little reactivity to B9 and fraction 20 even at 20 μg / mL, and little reactivity is observed when 40-fold more pAb is used, likely due to cross-reactivity with human ferritin.

[0176] Figure 32 graphically depicts the dynamic light scattering (DLS), or intensity size distribution data, which indicates a primary particle size of approximately 10-15 nm Rh in the purified protein sample, which is in good agreement with the expected diameter of 20-30 nm when counting linkers and domains.

[0177] Figure 33 graphically depicts data showing that CDv6 expressed fused to ferritin is properly folded. A rabbit polyclonal antibody specific for a human lambda epitope recognizes an exemplary ferritin-CDv6 domain fusion protein. A polyclonal rabbit antibody specific for a human lambda light chain epitope cross-linked both the CDv6 domain and the ferritin-CDv6 fusion protein assembled into a 24-mer structure, so it can be concluded that the CDv6 domain is properly folded when fused to ferritin. The rate of aggregation correlates with the size (radius) of the two proteins, suggesting that this rate is determined by diffusion.

[0178] FIG. 34A shows the sequence of an exemplary recombinant ferritin containing a modified CdV6 with a human epitope inserted therein (SEQ ID NO:35), where the underlined section is the CdV6 sequence, the bolded residues are the linker sequence, and the remainder of the sequence are rabbit ferritin residues.

[0179] FIG. 34B (SEQ ID NO:36) shows a heterodimer formed by non-covalent binding of (1) a chimeric recombinant antigen covalently linked to the amino terminus of a coiled-coil GBR2 motif (SEQ ID NO:27) to (2) a GBR1 motif (underlined) (SEQ ID NO:26) linked to the amino terminus of a ferritin molecule by the use of a non-immunogenic linker (bold) (SEQ ID NO:28), with the two subunits of the heterodimer non-covalently linked by the bond between the GBR1 and GBR2 motifs. In one embodiment, 24 heterodimers bind together to form a "ball" or core that presents the antigen to the external environment. Thus, when administered as an immunogen, this 24-mer is effective in generating an immune response against the presented antigen.

[0180] Although several embodiments of the present invention have been described, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, other embodiments are within the scope of the following claims.

Claims

1. A chimeric or recombinant polypeptide comprising: (a) a polypeptide derived from a first species, and (b) at least one heterologous amino acid sequence or amino acid residue derived from at least a second species; said at least one heterologous amino acid sequence or amino acid residue from said second or additional species is inserted into, joined to, engineered into, or replaces or substitutes a portion of the amino acid sequence of said polypeptide from said first species; the amino acid sequence of the chimeric or recombinant polypeptide consists essentially of an amino acid sequence derived from the first species; said amino acid sequence from said second species when inserted into, joined to, created within, or replacing or substituting a portion of said amino acid sequence of said polypeptide from said first species generates, forms or creates at least one new epitope on said polypeptide from said first species, said at least one new epitope being capable of generating a humoral antibody response by said first species specific for said at least one new epitope when said chimeric or recombinant polypeptide is administered to said first species; A chimeric or recombinant polypeptide, wherein when said chimeric or recombinant polypeptide is used to generate a humoral immune response from an animal of said first species, the polyclonal antibodies so generated in said first species specifically bind substantially only to said at least one new epitope and do not specifically bind substantially to said polypeptide from said first species lacking said at least one new epitope or epitopes created, formed or generated by said at least one heterologous amino acid sequence or amino acid residue from said second or additional species that is inserted into, joined to, engineered into, or replacing or substituting a portion of said polypeptide from said first species.

2. (a) the polypeptide from the second species is a homologue of the polypeptide from the first species; (b) the amino acid sequence from the at least one second species is homologous to the first species and is inserted into, joined to, engineered into, or replacing or substituting a portion of the amino acid sequence of the polypeptide from the first species, the at least one homologous second species sequence replacing all or substantially all of a structurally homologous section or portion of the amino acid sequence of the polypeptide from the first species; (c) the amino acid sequence from the at least one second species is homologous to the first species, and the at least one homologous second species sequence inserted into, joined to, engineered into, or replacing or substituting a portion of the amino acid sequence of the polypeptide from the first species is structurally homologous to the amino acid sequence of the polypeptide from the first species; (d) the homologue of the first species has at least about 25% to 99% sequence identity to its homologue in said second species; (e) the homologue in the first species has substantially the same secondary and / or tertiary structure as its homologue in the second species; (f) a homologue in a first species has at least about 25% to 99% sequence identity to its homologue in said second species and has substantially the same secondary and / or tertiary structure as its homologue in said second species, or a homologue in a first species has at least about 50% sequence identity to its homologue in said second species, or at least about 70% sequence identity to its homologue in said second species, or at least about 80% sequence identity to its homologue in said second species, or at least about 90% sequence identity to its homologue in said second species, and / or (g) the first polypeptide and the second polypeptide have a Z-score of about 2 to about 8 when aligned using a distance matrix alignment, or the first polypeptide and the second polypeptide have a Z-score of at least 8 when aligned using a distance matrix alignment. The chimeric or recombinant polypeptide of claim 1.

3. (a) said polypeptide from said first species and its homologue polypeptide from said second species are antibodies; (b) the polypeptide from the first species and the at least one heterologous amino acid sequence from the second species are derived from an antibody heavy chain or an antibody light chain; (c) the antibody heavy chain is an IgM, IgG, IgA, or IgE isotype heavy chain, or the light chain is a kappa or lambda light chain; (d) the first species is a mammalian species and the second species is a mammalian species, or the first species is a Phasianidae or Phasianidae species and the second species is a mammalian species; (e) the first species is a rabbit, a murine species, a sheep, a goat, a pig, a cow, a horse, or a chicken, and the second species is a human; (f) the murine species is a rat or a mouse; (g) at least about 80% to about 99% of the amino acid sequence of the chimeric or recombinant polypeptide is an amino acid sequence derived from the first species, and / or between about 1% and about 20% of the amino acid sequence of the chimeric or recombinant polypeptide is an amino acid sequence derived from the at least one second species; (h) one, two, three, four, five, six, seven, eight or more new epitopes are inserted into, joined to, engineered into, or replace or substitute for a portion of the polypeptide derived from the first species; (i) the at least one new epitope comprises an epitope derived from a cryptic surface of an antibody light chain, the cryptic surface being exposed only when the antibody light chain is free and not part of an IgG molecule containing both a light chain and a heavy chain; (j) the epitope generated, created, or formed by the at least one heterologous amino acid sequence from the at least one second species is (i) aligning the sequence of the polypeptide from the first species with its homologue polypeptide from the second species; (ii) determining one or more amino acid sequence differences between said polypeptide from said first species and its homologue polypeptide from said second species; (iii) selecting at least one amino acid sequence difference between said polypeptide from said first species and its homologue polypeptide from said second species; and (iv) modifying the sequence of the polypeptide from the first species to match or be identical to the selected at least one amino acid sequence from the homologous polypeptide of the second species. Designed by (k) selecting at least one amino acid sequence difference between the polypeptide from the first species and its homologue polypeptide from the second species comprises highlighting the determined one or more amino acid sequence differences between the polypeptide from the first species and its homologue polypeptide from the second species on a three-dimensional (3D) model or structure of the polypeptide from the second species, and selecting at least one amino acid sequence difference in or on an exposed or outer surface of the polypeptide; (l) the amino acid sequence from the at least one second species that is inserted into, joined to, engineered into, or replaces or substitutes for a portion of the amino acid sequence of the polypeptide from the first species comprises a sequence that is present in human IgG3 and not present in human IgG1, IgG2 or IgG4, or rabbit IgG, a sequence that is present in human IgG1 and not present in human IgG2, IgG3 or IgG4, or rabbit IgG, a sequence that is present in human IgG2 and not present in human IgG1, IgG3 or IgG4, or rabbit IgG, or a sequence that is present in human IgG4 and not present in human IgG1, IgG2 or IgG3, or rabbit IgG; (m) the chimeric or recombinant polypeptide is produced by a method further comprising removing one or more new epitopes from the at least one heterologous amino acid sequence or amino acid residue from the second or additional species after the new epitopes have been inserted into, joined to, engineered into, or replaced or substituted for a portion of the amino acid sequence of the polypeptide from the first species; (n) at least two or more different heterologous amino acid sequences or amino acid residues are inserted into, joined to, engineered into, or substituted or replaced by a portion of the amino acid sequence of the polypeptide derived from the first species; (o) the at least two or more different heterologous amino acid sequences or amino acid residues are from different animal species; (p) at least one of the at least two or more different heterologous amino acid sequences or amino acid residues is derived from a human and at least one of the at least two or more different heterologous amino acid sequences or amino acid residues is derived from a non-human or animal species; (q) at least one of the heterologous amino acid sequences or amino acid residues constitutes an artificial epitope not derived from the at least second species; (r) at least one of the heterologous amino acid sequences or amino acid residues constitutes an epitope originally derived from the at least second species that is immunologically silent in the first species (is unable to generate an antibody response in the first species) but has been modified to become an immunologically active epitope capable of generating an antibody response thereagainst by the first species; (s) at least one new epitope in the heterologous amino acid sequence or amino acid residues is modified such that antibodies generated by the first species against the modified new epitope bind weaker or slower than the equivalent unmodified new epitope; and / or (t) said chimeric or recombinant polypeptide further comprises at least one new epitope derived from at least a second species that is not homologous to said first species, said at least one new epitope capable of generating antibodies against said first species; A chimeric or recombinant polypeptide according to claim 1 or 2.

4. A recombinant polypeptide comprising a portion of a first polypeptide from a first species and at least a portion of a second polypeptide from a second species, wherein said at least a portion of said second polypeptide is a homolog of said first polypeptide, and said at least a homologous portion of said second polypeptide comprises an epitope not present in said first polypeptide.

5. (a) said portion of said at least one second polypeptide is at or substantially at the location of the homologous portion of said first polypeptide and replaces or substantially replaces said homologous portion of said first polypeptide; (b) the recombinant polypeptide comprises at least a portion of a second polypeptide and at least a portion of a third polypeptide, each of which is a homolog of a distinct sequence of the first species, wherein the portion of the second polypeptide and the portion of the third polypeptide each comprise an epitope not present in the first polypeptide; (c) the first polypeptide and the second polypeptide have a similar, or substantially the same, three-dimensional structure; (d) the first polypeptide and the second polypeptide have at least about 25% amino acid identity, or at least about 50% amino acid identity, or at least about 70% amino acid identity, or at least about 90% amino acid identity; (e) the first polypeptide and the second polypeptide have a Z-score of about 2 to about 8 when aligned using a distance matrix alignment, or the first polypeptide and the second polypeptide have a Z-score of at least 8 when aligned using a distance matrix alignment; (f) at least one sequence in the first polypeptide is removed and replaced by the homologous portion of the first polypeptide; (g) the at least one sequence removed from the second polypeptide comprises a sequence present in another member of the family to which the first and second polypeptides belong; (h) the at least one sequence that is removed comprises a sequence that is present in a domain in another member of the family to which the first and second polypeptides belong; (i) the at least one replaced sequence comprises an epitope specifically recognized by a monoclonal antibody; (j) the at least one replaced epitope comprises an epitope that contributes to at least one paratope subtype, and optionally the at least one replaced epitope is a dominant epitope; (k) the at least one replaced epitope is a weak epitope or an epitope that elicits a weak humoral response in the first species resulting in relatively low titers of antibodies; (l) the epitope in the second polypeptide is modified to reduce the affinity of antibodies generated by the first species compared to the unmodified epitope; (m) the recombinant polypeptide comprises a portion of a third polypeptide from a third species that comprises an epitope that is not present in either the first polypeptide or the second polypeptide; (n) at least one epitope present in another member of the family to which the first and second polypeptides belong is incorporated into the recombinant polypeptide; (o) incorporating into said recombinant polypeptide at least one epitope present in a domain in another member of the family to which said first and second polypeptides belong; (p) the epitope from the second polypeptide is modified to increase the affinity of an antibody that specifically recognizes the epitope from the second polypeptide or to generate affinity for the epitope from the second polypeptide by an antibody that specifically recognizes the epitope; (q) the first species is rabbit and the second species is human, and optionally the first polypeptide is a rabbit antibody light chain constant domain and the second polypeptide is a human antibody light chain constant domain; and / or (r) when said recombinant polypeptide is administered to said first species, said epitope is capable of giving rise to the production of antibodies that specifically bind to said epitope in said second polypeptide but not to said first polypeptide; The recombinant polypeptide of claim 4.

6. A recombinant nucleic acid encoding the chimeric or recombinant polypeptide described in claim 1.

7. (a) the recombinant nucleic acid further comprises, and is operably linked to, a transcriptional regulatory element, optionally comprising a promoter, optionally wherein the promoter is an inducible promoter or a constitutive promoter; (b) the recombinant nucleic acid further comprises a sequence encoding an additional protein or peptide moiety or domain, optionally comprising a purification moiety or domain to aid in the purification or isolation of the chimeric or recombinant antibody encoded by the recombinant nucleic acid, optionally comprising a histidine (poly-his) tag or a maltose binding protein; (c) the recombinant nucleic acid further comprises a sequence encoding a protease cleavage site located between the purification moiety or domain and the sequence encoding the chimeric or recombinant antibody, optionally the protease cleavage site is a Tobacco Etch Virus (TEV) protease cleavage site; (d) the recombinant nucleic acid comprises DNA, RNA, and / or synthetic or modified nucleotides that can be recognized by the cellular machinery to produce a protein; (e) the nucleic acid comprises a 3' cap or 3' methylation, a 5' untranslated region and / or a 3' untranslated region, and / or a polyadenine (poly-A) 5' tail; and / or (f) the nucleic acid or RNA comprises mRNA; The recombinant nucleic acid of claim 6.

8. An expression cassette, vector, recombinant virus, artificial chromosome, cosmid, or plasmid comprising the recombinant nucleic acid of claim 6.

9. A cell comprising a chimeric or recombinant polypeptide as described in claim 1, a recombinant nucleic acid as described in claim 6, or an expression cassette, vector, recombinant virus, artificial chromosome, cosmid, or plasmid as described in claim 8, wherein the cell is, as appropriate, a bacterial cell, a fungal cell, a mammalian cell, a yeast cell, an insect cell, or a plant cell.

10. 1. A method for producing polyclonal antibodies or polyclonal immune sera specific for or specifically binding to an epitope, comprising: (a) administering to a subject or immunizing the subject thereby a chimeric or recombinant polypeptide of claim 1; (b) administering to a subject a recombinant or chimeric nucleic acid according to claim 6, or an expression cassette, vector, recombinant virus, artificial chromosome, cosmid, or plasmid according to claim 8; or (c) administering the cell according to claim 9 to a subject. Including, The method, wherein the subject is the species from which the first polypeptide is derived and the epitope is from the species from which the second polypeptide is derived.

11. (a) the subject is a mammal or avian species, or the subject is a rabbit, a murine species, a sheep, a goat, a pig, a cow, a horse, or a chicken, optionally wherein the murine species is a rat or a mouse; (b) the recombinant or chimeric nucleic acid is an RNA or DNA construct; (c) the chimeric or recombinant polypeptide is produced by expressing a recombinant nucleic acid, or an expression cassette, vector, recombinant virus, artificial chromosome, cosmid, or plasmid in a cell, optionally wherein the cell is a bacterial cell, a fungal cell, a mammalian cell, a yeast cell, an insect cell, or a plant cell; (d) the method further comprises substantially isolating or purifying said chimeric or recombinant polypeptide prior to said administering to or immunizing said mammal; (e) the isolation or purification comprises the use of hydrophobic interaction chromatography (HIC), ion exchange chromatography (IEC), size exclusion chromatography (SEC), affinity purification, adsorption purification, or any combination thereof; (f) said administration (a), (b), or (c) is repeated 2 to 20 times, or repeated 2, 3, 4, 5, 6, 7, 8, 9, or 10 times, or repeated at intervals of 2-20 weeks or 3-16 weeks; (g) the method produces polyclonal antibodies or polyclonal immune sera that are substantially devoid of antibodies that are not specific or that do not specifically bind to the epitope, and optionally the method produces polyclonal antibodies or polyclonal immune sera that substantially comprise antibodies that are not specific or that do not specifically bind to a misfolded form of the epitope; (h) at least one sequence in the first polypeptide is removed and replaced by an epitope formed by a portion of the second polypeptide, optionally the at least one sequence in the first polypeptide that was removed is replaced by a sequence that comprises an epitope present in another member of the family to which the first and second polypeptides belong, optionally the at least one sequence in the first polypeptide that was removed is replaced by a sequence that comprises an epitope present in a domain in another member of the family to which the first and second polypeptides belong, optionally the at least one sequence in the first polypeptide that was replaced is replaced by a sequence that comprises an epitope specifically recognized by a monoclonal antibody; (i) the at least one sequence in the replaced first polypeptide is replaced by a sequence comprising an epitope that provides at least one paratope subtype, or the at least one sequence in the replaced first polypeptide is replaced by a sequence comprising an epitope that is a dominant epitope; (j) the at least one sequence in the replaced first polypeptide is replaced by a sequence containing an epitope that is a weak epitope or an epitope that elicits a weak humoral response resulting in relatively low titers of antibodies; (k) the epitope in the second polypeptide is modified to reduce the affinity of an antibody that specifically recognizes the epitope; (l) the recombinant polypeptide comprises a portion of a third polypeptide from a third species that comprises an epitope that is not present in either the first polypeptide or the second polypeptide; (m) at least one epitope present in another member of the family to which the first and second polypeptides belong is incorporated into the recombinant polypeptide; (n) at least one epitope present in a domain in another member of the family to which the first and second polypeptides belong is incorporated into the recombinant polypeptide; and / or (o) the epitope from the second polypeptide is modified to increase the affinity of an antibody that specifically recognizes the epitope from the second polypeptide or to generate affinity for the epitope from the second polypeptide by an antibody that specifically recognizes the epitope; The method of claim 10.

12. To generate polyclonal antibodies or polyclonal immune sera specific for or specifically binding to an epitope, (a) a chimeric or recombinant polypeptide according to claim 1; (b) the nucleic acid according to claim 6; (c) an expression cassette, vector, recombinant virus, artificial chromosome, cosmid, or plasmid according to claim 8; or (d) The cell according to claim 9. Use of.

13. A chimeric or recombinant polypeptide as described in claim 1, a nucleic acid as described in claim 6, an expression cassette, a vector, a recombinant virus, an artificial chromosome, a cosmid, or a plasmid as described in claim 8 for use in the generation of a polyclonal antibody or a polyclonal immune serum specific or specifically binding to an epitope.

14. 1. A chimeric or recombinant polypeptide comprising a ferritin polypeptide to which an immunogenic peptide or polypeptide is conjugated or attached by or through a substantially non-immunogenic linker, The immunogenic peptide or polypeptide comprises a chimeric or recombinant polypeptide of claim 1, wherein the ferritin polypeptide is of or derived from the first species.

15. (a) the ferritin polypeptide comprises at least one first coiled-coil protein or motif capable of binding to a second coiled-coil protein or motif (optionally comprising or linked to an immunogenic peptide, optionally covalently linked by a non-immunogenic linker), the first coiled-coil protein or motif being linked to the ferritin polypeptide by a non-immunogenic linker, resulting in a chimeric ferritin-coiled-coil protein polypeptide capable of appropriately folding into a tertiary or helical bundle structure; Optionally, said coiled-coil protein or motif is derived from said first species, and optionally said coiled-coil protein or motif derived from said first species binds to another coiled-coil protein or motif derived from said first species; Optionally, the ferritin polypeptide comprises two, three, four or more first coiled-coil proteins or motifs, Optionally, the coiled-coil protein or motif comprises gamma-aminobutyric acid type B receptor subunit 1 isoform X1 (GBR1) and / or gamma-aminobutyric acid type B receptor subunit 2 (GBR2), wherein the GBR1 is capable of selectively binding to the GBR2 motif; Optionally, the GBR1 motif is STNNNEEEKSRLLEKENRELEKIIAEKEERVSELRHQLQSR (SEQ ID NO:33), Optionally, the GBR2 motif is SVNQASTSRLEGLQSENHRLRMKITELDKDLEEVTMQLQDT (SEQ ID NO:34), (b) the amino acid sequence of the ferritin polypeptide has at least one His(6)-Lys-His(3) (SEQ ID NO:32) site or a plurality of His(6)-Lys-His(3) (SEQ ID NO:32) sites inserted therein; (c) the substantially non-immunogenic linker comprises a poly-G linker or a poly-(GGGGS) linker (SEQ ID NO:31); (d) the poly-(GGGGS) linker (SEQ ID NO: 31) is ５ (SEQ ID NO:29) comprising or consisting of a linker, (e) the non-immunogenic linker is attached to the amino terminus of the ferritin polypeptide; (f) the first species is rabbit or the ferritin polypeptide is derived from rabbit; (g) the immunogenic peptide or polypeptide comprises a chimeric immunogenic peptide or polypeptide, the chimeric immunogenic peptide or polypeptide comprising a human immunogenic sequence inserted into a rabbit peptide or polypeptide, the residue of the rabbit polypeptide being non-immunogenic when injected into a rabbit; and / or (h) the non-immunogenic rabbit peptide or polypeptide sequence is derived from a rabbit immunoglobulin polypeptide; 15. A chimeric or recombinant polypeptide according to claim 14.

16. 16. A product comprising a plurality of chimeric or recombinant polypeptides according to claim 14 or 15, Optionally, the article of manufacture comprises 24 of said chimeric or recombinant polypeptides; Optionally, each of said chimeric or recombinant polypeptides comprises a coiled-coil protein, and said coiled-coil proteins bind to each other.

17. A method for generating an epitope-specific antibody response in a rabbit, wherein the immune response comprises the generation of rabbit antibodies that are specific for (or specifically bind to) at least one human epitope, the method comprising administering to the rabbit a chimeric or recombinant polypeptide described in claim 14 or 15 in an amount sufficient to generate the epitope-specific antibody response.

18. The cell of claim 9 for use in producing a polyclonal antibody or polyclonal immune serum specific for or specifically binding to an epitope.

Images